Clinical trial results:
A phase III, randomized, controlled, observer-blind study to demonstrate effectiveness, immunogenicity and safety of GSK's meningococcal Group B and combined ABCWY vaccines when administered to healthy adolescents and young adults.

Summary

EudraCT number	2019-001666-15
Trial protocol	FI CZ EE Outside EU/EEA
Global end of trial date	13 September 2022

Results information

Result version number	v3
This version publication date	06 January 2024
First version publication date	27 March 2023
Version creation reason	

Trial information

Trial identification

Sponsor protocol code	205416

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline
Sponsor organisation address	Rue de l'Institut, 89, Rixensart, Belgium, 1330
Public contact	GSK Response Center, GlaxoSmithKline, 044 8664357343, GSKClinicalSupportHD@gsk.com
Scientific contact	GSK Response Center, GlaxoSmithKline, 044 8664357343, GSKClinicalSupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	24 October 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	13 September 2022
Global end of trial reached?	Yes
Global end of trial date	13 September 2022
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

•Effectiveness of rMenB+OMV NZ and MenABCWY vaccines -against a panel of N.meningitidis serogroup B strains at 1 month(M) after the 3 and 2-dose rMenB+OMV NZ series and last MenABCWY dose when compared to 1 M after MenACWY dose -As the percentages of subjects whose sera kill ≥70% of strains tested using enc-hSBA at 1 M after the 3 and 2-dose rMenB+OMV NZ series and 1 M after last MenABCWY dose •Lot-lot consistency of immune responses of 3 lots of MenACWY component of MenABCWY vaccine,as measured by hSBA GMTs at 1 M after last dose •Immunological non-inferiority: MenABCWY versus MenACWY as measured by percentages of subjects achieving a 4-fold rise in hSBA titers at 1 M after last MenABCWY dose and 1 M after MenACWY dose •Effectiveness non-inferiority: MenABCWY versus rMenB+OMV NZ in terms of percentage of samples with bactericidal serum activity at 1 M after last ABCWY dose and 1 M after 3 or 2 dose rMenB+OMV series •Safety and reactogenicity of MenB,MenABCWY and MenACWY vaccines

Protection of trial subjects:

Vaccine administration is to be preceded by a review of the participants medical history (including previous vaccination and possible occurrence of undesirable events) and a general physical examination at the first visit and symptom-directed physical examination before subsequent vaccinations. Protocol procedures including blood sampling were to be done by a qualified healthcare professional. Vaccines/products will be administered only to eligible participants who had no contraindications to any components of the vaccines/products. Participants will be followed-up for 6 months after third vaccination/product administration. The participants will be observed closely for at least 30 minutes following the administration of the vaccine(s)/product(s), with appropriate medical treatment readily available in case of anaphylaxis and/or syncope.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	14 August 2020
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 295
Country: Number of subjects enrolled	Canada: 229
Country: Number of subjects enrolled	Czechia: 750
Country: Number of subjects enrolled	Estonia: 127
Country: Number of subjects enrolled	Finland: 819
Country: Number of subjects enrolled	Türkiye: 333
Country: Number of subjects enrolled	United States: 1085
Worldwide total number of subjects	3638
EEA total number of subjects	1696

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	702
Adolescents (12-17 years)	1459
Adults (18-64 years)	1477
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

As pre-specified in protocol: -Participant flow, Baseline characteristics, AEs, Effectiveness, and immunogenicity data are presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group. - Lot-to-lot consistency analysis data are presented for individual ABCWY lot groups (ABCWY-1, ABCWY-2 and ABCWY-3).

Pre-assignment

Screening details:

Out of 3657 participants enrolled,19 participants did not receive vaccination as they did not meet the eligibility criteria, therefore only 3638 participants were included in the Exposed Set and started the study.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind[1]
Roles blinded	Monitor, Data analyst

Blinding implementation details:

Observer-blinded study. Recipients & study evaluators will be unaware of vaccine administered.

Arms

Are arms mutually exclusive?	Yes
Arm title	MenB_0_2_6 Group

Arm description:

Participants received 3 doses of rMenB+OMV NZ vaccine on Day 1, Day 61 and Day 181. Participants received 1 dose of MenACWY vaccine at Day 211 as a standard of care.

Arm type	Experimental
Investigational medicinal product name	Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)
Investigational medicinal product code	
Other name	Menveo
Pharmaceutical forms	Powder and solution for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

1 dose of MenACWY vaccine at Day 211

Investigational medicinal product name	Meningococcal Group B Vaccine (rMenB+OMV NZ)
Investigational medicinal product code	
Other name	Bexsero
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 doses of rMenB+OMV NZ vaccine at Day 1, Day 61 and Day 181

Arm title	MenB_0_6 Group

Arm description:

Participants received 2 doses of rMenB+OMV NZ vaccine on Day 1, and Day 181, 1 dose of MenACWY vaccine on Day 61. Participants received 1 dose of Placebo on Day 211 to maintain blinding.

Arm type	Experimental

Investigational medicinal product name	Meningococcal Group B Vaccine (rMenB+OMV NZ)
Investigational medicinal product code	
Other name	Bexsero
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 doses of rMenB+OMV NZ vaccine at Day 1 and Day 181

Investigational medicinal product name	Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)
Investigational medicinal product code	
Other name	Menveo
Pharmaceutical forms	Powder and solution for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

1 dose of MenACWY vaccine at Day 61

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

1 dose of Placebo at Day 211

Arm title	ABCWY_Pooled

Arm description:

Participants received 2 doses of either MenABCWY Lot 1, Lot 2, or Lot 3 vaccine on Day 1 and Day 181 and 1 dose of placebo on Day 61. Participants received 1 dose of placebo on Day 211 to maintain blinding. To evaluate the effectiveness of 2 doses of the MenABCWY vaccines against rMenB+OMV and MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

Arm type	Experimental
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 dose of Placebo at Day 61 and Day 211

Investigational medicinal product name	Combined Meningococcal Groups A, B, C, W and Y vaccine (MenABCWY)
Investigational medicinal product code	MenABCWY
Other name	
Pharmaceutical forms	Powder and suspension for suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 doses of MenABCWY vaccine at Day 1 and Day 181

Arm title	ACWY Group

Arm description:

Participants received 1 dose of MenACWY vaccine at Day 1,1 dose of placebo at Day 61 and 1 dose of rMenB+OMV NZ vaccine on Day 181. Participants received 1 dose of rMenB+OMV NZ vaccine on Day 211 as standard of care.

Arm type	Active comparator

Investigational medicinal product name	Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)
Investigational medicinal product code	
Other name	Menveo
Pharmaceutical forms	Powder and solution for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

1 dose of MenACWY vaccine at Day 1

Investigational medicinal product name	Meningococcal Group B Vaccine (rMenB+OMV NZ)
Investigational medicinal product code	
Other name	Bexsero
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 doses of rMenB+OMV NZ vaccine at Day 181 and Day 211

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

1 dose of Placebo at Day 61

Notes:

[1] - The roles blinded appear to be inconsistent with a double blind trial.

Justification: This is an Observer-blinded study. Recipients & study evaluators were unaware of the vaccine administered.

Number of subjects in period 1	MenB_0_2_6 Group	MenB_0_6 Group	ABCWY_Pooled
Started	897	906	1657
Completed	797	811	1497
Not completed	100	95	160
Consent withdrawn by subject	46	38	54
Adverse event, non-fatal	7	6	11
Not specified	1	-	1
MIGRATED / MOVED FROM THE STUDY AREA	6	7	9
Lost to follow-up	32	36	69
Protocol deviation	8	8	16

Number of subjects in period 1	ACWY Group
Started	178
Completed	163
Not completed	15
Consent withdrawn by subject	7
Adverse event, non-fatal	1
Not specified	1
MIGRATED / MOVED FROM THE STUDY AREA	1
Lost to follow-up	4

Protocol deviation	1

Baseline characteristics

Reporting groups	
Reporting group title	MenB_0_2_6 Group
Reporting group description:	
Participants received 3 doses of rMenB+OMV NZ vaccine on Day 1, Day 61 and Day 181. Participants received 1 dose of MenACWY vaccine at Day 211 as a standard of care.	
Reporting group title	MenB_0_6 Group
Reporting group description:	
Participants received 2 doses of rMenB+OMV NZ vaccine on Day 1, and Day 181, 1 dose of MenACWY vaccine on Day 61. Participants received 1 dose of Placebo on Day 211 to maintain blinding.	
Reporting group title	ABCWY_Pooled
Reporting group description:	
Participants received 2 doses of either MenABCWY Lot 1, Lot 2, or Lot 3 vaccine on Day 1 and Day 181 and 1 dose of placebo on Day 61. Participants received 1 dose of placebo on Day 211 to maintain blinding. To evaluate the effectiveness of 2 doses of the MenABCWY vaccines against rMenB+OMV and MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.	
Reporting group title	ACWY Group
Reporting group description:	
Participants received 1 dose of MenACWY vaccine at Day 1,1 dose of placebo at Day 61 and 1 dose of rMenB+OMV NZ vaccine on Day 181. Participants received 1 dose of rMenB+OMV NZ vaccine on Day 211 as standard of care.	

Reporting group values	MenB_0_2_6 Group	MenB_0_6 Group	ABCWY_Pooled
Number of subjects	897	906	1657
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	183	172	320
Adolescents (12-17 years)	349	368	666
Adults (18-64 years)	365	366	671
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous Units: years			
arithmetic mean	16.5	16.5	16.5
standard deviation	± 4.7	± 4.7	± 4.7
Sex: Female, Male Units: Participants			
Female	464	446	933
Male	433	460	724
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native	5	5	3
Asian	43	60	71
Black or African American	33	29	59

Native Hawaiian or Other Pacific Islander	3	1	3
Other, Unspecified	17	20	29
White	796	791	1492

Reporting group values	ACWY Group	Total	
Number of subjects	178	3638	
Age categorical Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	27	702	
Adolescents (12-17 years)	76	1459	
Adults (18-64 years)	75	1477	
From 65-84 years	0	0	
85 years and over	0	0	
Age continuous Units: years			
arithmetic mean	16.9		
standard deviation	± 4.6	-	
Sex: Female, Male Units: Participants			
Female	100	1943	
Male	78	1695	
Race/Ethnicity, Customized Units: Subjects			
American Indian or Alaska Native	0	13	
Asian	9	183	
Black or African American	6	127	
Native Hawaiian or Other Pacific Islander	0	7	
Other, Unspecified	1	67	
White	162	3241	

End points

End points reporting groups

Reporting group title	MenB_0_2_6 Group
Reporting group description:	
Participants received 3 doses of rMenB+OMV NZ vaccine on Day 1, Day 61 and Day 181. Participants received 1 dose of MenACWY vaccine at Day 211 as a standard of care.	
Reporting group title	MenB_0_6 Group
Reporting group description:	
Participants received 2 doses of rMenB+OMV NZ vaccine on Day 1, and Day 181, 1 dose of MenACWY vaccine on Day 61. Participants received 1 dose of Placebo on Day 211 to maintain blinding.	
Reporting group title	ABCWY_Pooled
Reporting group description:	
Participants received 2 doses of either MenABCWY Lot 1, Lot 2, or Lot 3 vaccine on Day 1 and Day 181 and 1 dose of placebo on Day 61. Participants received 1 dose of placebo on Day 211 to maintain blinding. To evaluate the effectiveness of 2 doses of the MenABCWY vaccines against rMenB+OMV and MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.	
Reporting group title	ACWY Group
Reporting group description:	
Participants received 1 dose of MenACWY vaccine at Day 1,1 dose of placebo at Day 61 and 1 dose of rMenB+OMV NZ vaccine on Day 181. Participants received 1 dose of rMenB+OMV NZ vaccine on Day 211 as standard of care.	
Subject analysis set title	ABCWY-1 Group
Subject analysis set type	Per protocol
Subject analysis set description:	
Participants received 2 doses of MenABCWY lot 1 vaccine at Day 1 and Day 181 and 2 doses of placebo at Day 61 and Day 211.	
Subject analysis set title	ABCWY-2 Group
Subject analysis set type	Per protocol
Subject analysis set description:	
Participants received 2 doses of MenABCWY lot 2 vaccine at Day 1 and Day 181 and 2 doses of placebo at Day 61 and Day 211.	
Subject analysis set title	ABCWY-3 Group
Subject analysis set type	Per protocol
Subject analysis set description:	
Participants received 2 doses of MenABCWY lot 3 vaccine at Day 1 and Day 181 and 2 doses of placebo at Day 61 and Day 211.	

Primary: Percentage of blood samples without bactericidal serum activity against each of the endemic US N. meningitidis serogroup B strains at 1 month after the 3-dose (0,2,6-M), 2-dose(0,6-M) vaccination schedule of rMenB+OMV and 1 dose of MenACWY

End point title	Percentage of blood samples without bactericidal serum activity against each of the endemic US N. meningitidis serogroup B strains at 1 month after the 3-dose (0,2,6-M), 2-dose(0,6-M) vaccination schedule of rMenB+OMV and 1 dose of MenACWY[1]

End point description:

The effectiveness (test-based) of rMenB+OMV vaccine at 1 month after the 3 doses in MenB_0_2_6 group and 1 month after the 2 dose schedule in MenB_0_6 group when compared to one dose of MenACWY vaccination in ACWY group, against a panel of N. meningitidis serogroup B strains was measured in terms of percentage of samples without bactericidal activity using endogenous complement human Serum Bactericidal Assay (enc-hSBA), which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. Participants were randomly selected for testing against each strain therefore only a subset of participants were tested for each of the strains. Number of Participants analyzed = Total number of participants included in PPS.
Analysis was performed on blood samples collected from Per Protocol Set (PPS).

End point type	Primary

End point timeframe:

At 1 month after vaccination schedule (i.e., Day 211 for MenB_0_2_6 group [3-dose schedule] and MenB_0_6 group, and Day 31 for ACWY group)

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: As specified in the Protocol, the analysis assesses the effectiveness of the MenABCWY vaccine compared to the rMenB+OMV vaccine in terms of the percentage of samples with bactericidal serum activity.

End point values	MenB_0_2_6 Group	MenB_0_6 Group	ACWY Group	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	740	751	147	
Units: Percentage of blood samples				
number (not applicable)				
Number of Blood samples (N=25596,26142,4374)	13.3	14.4	79	

Statistical analyses

Statistical analysis title	Statistical analysis 2

Statistical analysis description:

To demonstrate the effectiveness of the rMenB+OMV NZ vaccine against a randomly selected panel of endemic US N. meningitidis serogroup B invasive disease strains as measured by bactericidal activity using enc-hSBA at 1 month after the 2-dose (0,6-M) schedule in MenB_0_6 group when compared to 1 month after the MenACWY dose in the ACWY group.

Comparison groups	MenB_0_6 Group v ACWY Group
Number of subjects included in analysis	898
Analysis specification	Pre-specified
Analysis type	other[2]
Parameter estimate	VE
Point estimate	81.8
Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	80.4
upper limit	83.1

Notes:

[2] - Effectiveness of rMenB+OMV NZ vaccine is demonstrated if the LL of the 2-sided 97.5% CI for VE against the selected strain panel between the MenB_0_ 6 and the ACWY groups is above 65%.
VE is defined as 1- RR = (1- percentage of samples without bactericidal serum activity at 1:4 dilution in MenB group / percentage of samples without bactericidal serum activity at 1:4 dilution in the ACWY group) x100 percentage.

Statistical analysis title	Statistical analysis 1

Statistical analysis description:

To demonstrate the effectiveness of the rMenB+OMV NZ vaccine against a randomly selected panel of endemic US N. meningitidis serogroup B invasive disease strains as measured by bactericidal activity using enc-hSBA at 1 month after the 3-dose (0,2,6-months) schedule in MenB_0_2_6 group when compared to 1 month after the MenACWY dose in the ACWY group.

Comparison groups	MenB_0_2_6 Group v ACWY Group

Number of subjects included in analysis	887
Analysis specification	Pre-specified
Analysis type	other[3]
Parameter estimate	VE (Vaccine Effectiveness)
Point estimate	83.2
Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	81.9
upper limit	84.4

Notes:

[3] - Effectiveness of rMenB+OMV NZ vaccine is demonstrated if the LL of the 2-sided 97.5% CI for Vaccine Effectiveness (VE) against the selected strain panel between the MenB_0_2_6 and the ACWY groups is above 65%. VE is defined as 1- Risk Ratio (RR) = (1- percentage of samples without bactericidal serum activity at 1:4 dilution in MenB group / percentage of samples without bactericidal serum activity at 1:4 dilution in the ACWY group) x100 percentage.

Primary: Percentage of blood samples without bactericidal serum activity against each of the endemic US N. meningitidis serogroup B strains at 1 month after the 2-dose (0,2-M) vaccination schedule of rMenB+OMV and 1 dose of MenACWY

End point title	Percentage of blood samples without bactericidal serum activity against each of the endemic US N. meningitidis serogroup B strains at 1 month after the 2-dose (0,2-M) vaccination schedule of rMenB+OMV and 1 dose of MenACWY[4]

End point description:

The effectiveness (test-based) of rMenB+OMV vaccine at 1 month after the 2 doses in MenB_0_2_6 group when compared to one dose of MenACWY vaccination in ACWY group, against a panel of N. meningitidis serogroup B strains was measured in terms of percentage of samples without bactericidal activity using endogenous complement human Serum Bactericidal Assay (enc-hSBA), which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. Participants were randomly selected for testing against each strain therefore only a subset of participants were tested for each of the strains. Number of Participants analyzed = Total number of participants included in PPS.
Analysis was performed on blood samples collected from Per Protocol Set (PPS).

End point type	Primary

End point timeframe:

At 1 month after vaccination schedule (i.e., Day 91 for the MenB_0_2_6 group [2-dose schedule] and Day 31 for ACWY group)

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: As specified in the Protocol, the analysis assesses the effectiveness of the MenABCWY vaccine compared to the rMenB+OMV vaccine in terms of the percentage of samples with bactericidal serum activity.

End point values	MenB_0_2_6 Group	ACWY Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	740	147		
Units: Percentage of blood samples				
number (not applicable)				
Number of Blood samples (N=27569,4374)	16.8	79		

Statistical analyses

Statistical analysis title	Statistical analysis 1

Statistical analysis description:

To demonstrate the effectiveness of the rMenB+OMV NZ vaccine against a randomly selected panel of endemic US N. meningitidis serogroup B invasive disease strains as measured by bactericidal activity using enc-hSBA at 1 month after the 2-dose (0,2-M) schedule in MenB_0_2_6 group when compared to 1 month after the MenACWY dose in the ACWY group.

Comparison groups	MenB_0_2_6 Group v ACWY Group
Number of subjects included in analysis	887
Analysis specification	Pre-specified
Analysis type	other[5]
Parameter estimate	VE
Point estimate	78.7
Confidence interval	
level	Other: 97.5 %
sides	2-sided
lower limit	77.2
upper limit	80.1

Notes:

[5] - Effectiveness of rMenB+OMV NZ vaccine is demonstrated if the LL of the 2-sided 97.5% CI for VE against the selected strain panel between the MenB_0_2_6 and the ACWY groups is above 65%. VE is defined as 1- RR = (1- percentage of samples without bactericidal serum activity at 1:4 dilution in MenB group / percentage of samples without bactericidal serum activity at 1:4 dilution in the ACWY group) x100 percentage.

Primary: Geometric mean titers (GMTs) against serogroups A, C, W and Y for each lot (ABCWY-1 Group, ABCWY-2 Group and ABCWY-3 Group) at 1 month after the last vaccination of MenABCWY

End point title	Geometric mean titers (GMTs) against serogroups A, C, W and Y for each lot (ABCWY-1 Group, ABCWY-2 Group and ABCWY-3 Group) at 1 month after the last vaccination of MenABCWY

End point description:

Immune response was measured in terms of hSBA GMTs directed against serogroups A, C, W and Y. As pre- specified in the protocol, the data reported in this outcome measures data were presented for individual lots to demonstrate the consistency of the immune response of 3 lots (ABCWY- 1 Group, ABCWY-2 Group, and ABCWY-3 Group) of the ACWY component of the MenABCWY vaccine. Analysis was performed on PPS.

End point type	Primary

End point timeframe:

At 1 month after the last vaccination of MenABCWY (Day 211)

End point values	ABCWY-1 Group	ABCWY-2 Group	ABCWY-3 Group	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	452	449	458	
Units: Titers				
geometric mean (confidence interval 95%)				
Men A (N=448,443,454)	336.4 (299.3 to 378.0)	349.9 (311.5 to 393.0)	390.4 (347.4 to 438.8)	
Men C (N= 448,449,456)	1036.7 (877.6 to 1224.5)	1130.2 (958.1 to 1333.4)	888.4 (752.1 to 1049.2)	
Men W (N= 452,449,458)	564.5 (497.9 to 639.9)	635.5 (561.0 to 719.9)	640.1 (564.6 to 725.6)	
Men Y (N=451,449,457)	536.7 (464.5 to 620.2)	623.9 (540.4 to 720.2)	644.3 (557.6 to 744.6)	

Statistical analyses

Statistical analysis title	Statistical analysis 1

Statistical analysis description:

To demonstrate lot-to-lot consistency of the immune responses of ABCWY-1 and ABCWY-2 lots of the MenACWY component of the MenABCWY vaccine, as measured by hSBA GMTs directed against serogroup A at 1 month after last vaccination (Day 211).

Comparison groups	ABCWY-1 Group v ABCWY-2 Group
Number of subjects included in analysis	901
Analysis specification	Pre-specified
Analysis type	equivalence[6]
Parameter estimate	GMT ratio
Point estimate	0.96
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.84
upper limit	1.1

Notes:

[6] - Lot-to-lot consistency is claimed if the 2-sided 95% CIs for the ratio of hSBA GMTs of antibodies against each of the serogroups A, C, W and Y are within the [0.5;2.0] equivalence interval for each pair of lots.

Statistical analysis title	Statistical analysis 2

Statistical analysis description:

To demonstrate lot-to-lot consistency of the immune responses of ABCWY-1 and ABCWY-3 lots of the MenACWY component of the MenABCWY vaccine, as measured by hSBA GMTs directed against serogroup A at 1 month after last vaccination (Day 211).

Comparison groups	ABCWY-1 Group v ABCWY-3 Group
Number of subjects included in analysis	910
Analysis specification	Pre-specified
Analysis type	equivalence[7]
Parameter estimate	GMT ratio
Point estimate	0.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.75
upper limit	0.98

Notes:

[7] - Lot-to-lot consistency is claimed if the 2-sided 95% CIs for the ratio of hSBA GMTs of antibodies against each of the serogroups A, C, W and Y is within the [0.5;2.0] equivalence interval for each pair of lots.

Statistical analysis title	Statistical analysis 5

Statistical analysis description:

To demonstrate lot-to-lot consistency of the immune responses of ABCWY-1 and ABCWY-3 lots of the MenACWY component of the MenABCWY vaccine, as measured by hSBA GMTs directed against serogroup C at 1 month after last vaccination (Day 211).

Comparison groups	ABCWY-1 Group v ABCWY-3 Group
Number of subjects included in analysis	910
Analysis specification	Pre-specified
Analysis type	equivalence[8]
Parameter estimate	GMT ratio
Point estimate	1.17
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.97
upper limit	1.41

Notes:

[8] - Lot-to-lot consistency is claimed if the 2-sided 95% CIs for the ratio of hSBA GMTs of antibodies against each of the serogroups A, C, W and Y is within the [0.5;2.0] equivalence interval for each pair of lots.

Statistical analysis title	Statistical analysis 12

Statistical analysis description:

To demonstrate lot-to-lot consistency of the immune responses of ABCWY-2 and ABCWY-3 lots of the MenACWY component of the MenABCWY vaccine, as measured by hSBA GMTs directed against serogroup Y at 1 month after last vaccination (Day 211).

Comparison groups	ABCWY-2 Group v ABCWY-3 Group
Number of subjects included in analysis	907
Analysis specification	Pre-specified
Analysis type	equivalence[9]
Parameter estimate	GMT ratio
Point estimate	0.97
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.82
upper limit	1.14

Notes:

[9] - Lot-to-lot consistency is claimed if the 2-sided 95% CIs for the ratio of hSBA GMTs of antibodies against each of the serogroups A, C, W and Y is within the [0.5;2.0] equivalence interval for each pair of lots.

Statistical analysis title	Statistical analysis 7

Statistical analysis description:

To demonstrate lot-to-lot consistency of the immune responses of ABCWY-1 and ABCWY-2 lots of the MenACWY component of the MenABCWY vaccine, as measured by hSBA GMTs directed against serogroup W at 1 month after last vaccination (Day 211).

Comparison groups	ABCWY-1 Group v ABCWY-2 Group
Number of subjects included in analysis	901
Analysis specification	Pre-specified
Analysis type	equivalence[10]
Parameter estimate	GMT ratio
Point estimate	0.89
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.77
upper limit	1.02

Notes:

[10] - Lot-to-lot consistency is claimed if the 2-sided 95% CIs for the ratio of hSBA GMTs of antibodies against each of the serogroups A, C, W and Y are within the [0.5;2.0] equivalence interval for each pair of lots.

Statistical analysis title	Statistical analysis 8

Statistical analysis description:

To demonstrate lot-to-lot consistency of the immune responses of ABCWY-1 and ABCWY-3 lots of the MenACWY component of the MenABCWY vaccine, as measured by hSBA GMTs directed against serogroup W at 1 month after last vaccination (Day 211).

Comparison groups	ABCWY-1 Group v ABCWY-3 Group
Number of subjects included in analysis	910
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	GMT ratio
Point estimate	0.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.77
upper limit	1.02

Statistical analysis title	Statistical analysis 9

Statistical analysis description:

To demonstrate lot-to-lot consistency of the immune responses of ABCWY-2 and ABCWY-3 lots of the MenACWY component of the MenABCWY vaccine, as measured by hSBA GMTs directed against serogroup W at 1 month after last vaccination (Day 211).

Comparison groups	ABCWY-2 Group v ABCWY-3 Group
Number of subjects included in analysis	907
Analysis specification	Pre-specified
Analysis type	equivalence[11]
Parameter estimate	GMT ratio
Point estimate	0.99
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.86
upper limit	1.14

Notes:

[11] - Lot-to-lot consistency is claimed if the 2-sided 95% CIs for the ratio of hSBA GMTs of antibodies against each of the serogroups A, C, W and Y is within the [0.5;2.0] equivalence interval for each pair of lots.

Statistical analysis title	Statistical analysis 10

Statistical analysis description:

To demonstrate lot-to-lot consistency of the immune responses of ABCWY-1 and ABCWY-2 lots of the MenACWY component of the MenABCWY vaccine, as measured by hSBA GMTs directed against serogroup Y at 1 month after last vaccination (Day 211).

Comparison groups	ABCWY-1 Group v ABCWY-2 Group

Number of subjects included in analysis	901
Analysis specification	Pre-specified
Analysis type	equivalence[12]
Parameter estimate	GMT ratio
Point estimate	0.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.73
upper limit	1.01

Notes:

[12] - Lot-to-lot consistency is claimed if the 2-sided 95% CIs for the ratio of hSBA GMTs of antibodies against each of the serogroups A, C, W and Y are within the [0.5;2.0] equivalence interval for each pair of lots.

Statistical analysis title	Statistical analysis 11

Statistical analysis description:

To demonstrate lot-to-lot consistency of the immune responses of ABCWY-1 and ABCWY-3 lots of the MenACWY component of the MenABCWY vaccine, as measured by hSBA GMTs directed against serogroup Y at 1 month after last vaccination (Day 211).

Comparison groups	ABCWY-1 Group v ABCWY-3 Group
Number of subjects included in analysis	910
Analysis specification	Pre-specified
Analysis type	equivalence[13]
Parameter estimate	GMT ratio
Point estimate	0.83
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.71
upper limit	0.98

Notes:

[13] - Lot-to-lot consistency is claimed if the 2-sided 95% CIs for the ratio of hSBA GMTs of antibodies against each of the serogroups A, C, W and Y is within the [0.5;2.0] equivalence interval for each pair of lots.

Statistical analysis title	Statistical analysis 4

Statistical analysis description:

To demonstrate lot-to-lot consistency of the immune responses of ABCWY-1 and ABCWY-2 lots of the MenACWY component of the MenABCWY vaccine, as measured by hSBA GMTs directed against serogroup C at 1 month after last vaccination (Day 211).

Comparison groups	ABCWY-1 Group v ABCWY-2 Group
Number of subjects included in analysis	901
Analysis specification	Pre-specified
Analysis type	equivalence[14]
Parameter estimate	GMT ratio
Point estimate	0.92
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.76
upper limit	1.11

Notes:

[14] - Lot-to-lot consistency is claimed if the 2-sided 95% CIs for the ratio of hSBA GMTs of antibodies against each of the serogroups A, C, W and Y are within the [0.5;2.0] equivalence interval for each pair of lots.

Statistical analysis title	Statistical analysis 3

Statistical analysis description:

To demonstrate lot-to-lot consistency of the immune responses of ABCWY-2 and ABCWY-3 lots of the MenACWY component of the MenABCWY vaccine, as measured by hSBA GMTs directed against serogroup A at 1 month after last vaccination (Day 211).

Comparison groups	ABCWY-2 Group v ABCWY-3 Group
Number of subjects included in analysis	907
Analysis specification	Pre-specified
Analysis type	equivalence[15]
Parameter estimate	GMT ratio
Point estimate	0.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.78
upper limit	1.02

Notes:

[15] - Lot-to-lot consistency is claimed if the 2-sided 95% CIs for the ratio of hSBA GMTs of antibodies against each of the serogroups A, C, W and Y is within the [0.5;2.0] equivalence interval for each pair of lots.

Statistical analysis title	Statistical analysis 6

Statistical analysis description:

To demonstrate lot-to-lot consistency of the immune responses of ABCWY-2 and ABCWY-3 lots of the MenACWY component of the MenABCWY vaccine, as measured by hSBA GMTs directed against serogroup C at 1 month after last vaccination (Day 211).

Comparison groups	ABCWY-2 Group v ABCWY-3 Group
Number of subjects included in analysis	907
Analysis specification	Pre-specified
Analysis type	equivalence[16]
Parameter estimate	GMT ratio
Point estimate	1.27
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.05
upper limit	1.54

Notes:

[16] - Lot-to-lot consistency is claimed if the 2-sided 95% CIs for the ratio of hSBA GMTs of antibodies against each of the serogroups A, C, W and Y is within the [0.5;2.0] equivalence interval for each pair of lots.

Primary: Percentage of participants whose sera kill >=70% of the strains tested using enc-hSBA at 1 month after the 2-dose (0,2-M) schedule of rMenB+OMV

End point title	Percentage of participants whose sera kill >=70% of the strains tested using enc-hSBA at 1 month after the 2-dose (0,2-M) schedule of rMenB+OMV[17][18]

End point description:

The effectiveness (responder-based) of the rMenB+OMV NZ vaccine was measured in terms of percentage of participants whose sera kill >=70% of the strains tested using enc-hSBA, calculated based on Clopper Pearson method. Effectiveness is demonstrated if Lower Limit (LL) of the two-sided 97.5% CI for the percentages of subjects whose sera kill ≥70% of strains is above 65%. Analysis was

performed on the FAS.

End point type	Primary

End point timeframe:

At 1 month after vaccination schedule (i.e., Day 91 for the MenB_0_2_6 group [2-dose schedule])

Notes:

[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: As specified in the Protocol, the analysis assesses the effectiveness of the rMenB+OMV vaccine by assessing the percentages of subjects whose sera kill ≥70% of strains tested.

End point values	MenB_0_2_6 Group			
Subject group type	Reporting group			
Number of subjects analysed	831			
Units: Percentage of participants				
number (confidence interval 97.5%)	84.8 (81.8 to 87.5)			

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of participants whose sera kill Greater Than or Equal to (>=) 70% of the strains tested using enc-hSBA at 1 month after the 3-dose (0,2,6-M) schedule of rMenB+OMV and 2-dose(0,6-M) schedule of rMenB+OMV

End point title	Percentage of participants whose sera kill Greater Than or Equal to (>=) 70% of the strains tested using enc-hSBA at 1 month after the 3-dose (0,2,6-M) schedule of rMenB+OMV and 2-dose(0,6-M) schedule of rMenB+OMV[19][20]

End point description:

The effectiveness (responder-based) of the rMenB+OMV NZ vaccine was measured in terms of percentage of participants whose sera kill >=70% of the strains tested using enc-hSBA, calculated based on Clopper Pearson method. Effectiveness is demonstrated if Lower Limit (LL) of the two-sided 97.5% CI for the percentages of subjects whose sera kill ≥70% of strains is above 65%. Analysis was performed on the Full Analysis Set (FAS).

End point type	Primary

End point timeframe:

At 1 month after vaccination schedule (i.e., Day 211 for MenB_0_2_6 group [3-dose schedule] and MenB_0_6 group)

Notes:

[19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: As specified in the Protocol, the analysis assesses the effectiveness of the rMenB+OMV vaccine by assessing the percentages of subjects whose sera kill ≥70% of strains tested.

End point values	MenB_0_2_6 Group	MenB_0_6 Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	790	813		
Units: Percentage of participants				
number (confidence interval 97.5%)	93.4 (91.2 to 95.2)	89.8 (87.2 to 92)		

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of participants with 4-fold rise in hSBA titers against N. meningitidis serogroups A, C, W and Y at 1 month after last MenABCWY vaccination (pooled lots) and MenACWY vaccination (for the ACWY Group), relative to baseline

End point title	Percentage of participants with 4-fold rise in hSBA titers against N. meningitidis serogroups A, C, W and Y at 1 month after last MenABCWY vaccination (pooled lots) and MenACWY vaccination (for the ACWY Group), relative to baseline[21]

End point description:

Four-fold rise is defined as: If the pre-vaccination hSBA titer is < 4, then post-vaccination hSBA titer should be >= 16 . If the pre-vaccination hSBA titer is >= limit of detection (LOD) but < LL of quantification (LLOQ), then post-vaccination hSBA titer should be >= 4 times the LLOQ. If the pre-vaccination hSBA titer is >= LLOQ, then post-vaccination hSBA titer should be >= 4 times the pre-vaccination hSBA titer. As pre-specified in the protocol, data reported in this outcome measure were presented for ACWY group, ABCWY pooled group to evaluate the immunological non-inferiority of 2 doses of the MenABCWY vaccines against MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY- 3 groups were pooled into a single group. Analysis was performed on PPS.

End point type	Primary

End point timeframe:

At 1 month after vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 31 for the ACWY Group) compared to Day 1 (baseline)

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: As specified in the Protocol, the analysis assesses the effectiveness of the rMenB+OMV vaccine compared to one dose of MenACWY vaccination in the ACWY group.

End point values	ABCWY_Pooled	ACWY Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1196	119		
Units: Percentage of participants				
number (confidence interval 95%)				
Men A (N=1170,112)	97.0 (95.9 to 97.9)	85.7 (77.8 to 91.6)		
Men C (N=1189,114)	97.2 (96.1 to 98.1)	50.0 (40.5 to 59.5)		
Men W (N=1185,115)	97.0 (95.9 to 97.9)	61.7 (52.2 to 70.6)		
Men Y (N=1196,119)	96.7 (95.6 to 97.7)	69.7 (60.7 to 77.8)		

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

To demonstrate the immunological non- inferiority of the MenABCWY vaccine compared to the MenACWY vaccine in participants without a previous MenACWY vaccination (unprimed) as measured by the percentages of participants, achieving a 4- fold rise in hSBA titers against N. meningitidis serogroup A at 1 month after the last MenABCWY vaccination (Day 211) and 1 month after the MenACWY vaccination.

Comparison groups	ABCWY_Pooled v ACWY Group
Number of subjects included in analysis	1315
Analysis specification	Pre-specified
Analysis type	non-inferiority[22]
Parameter estimate	Difference in percentage of participants
Point estimate	11.29
Confidence interval	
level	95 %
sides	2-sided
lower limit	5.88
upper limit	19.01

Notes:

[22] - Non-inferiority of MenABCWY vaccine is demonstrated if the LL of the 2-sided 95% CI for the difference in percentage of participants with 4-fold rise between the 2 groups is above -10%.

Statistical analysis title	Statistical Analysis 3

Statistical analysis description:

To demonstrate the immunological non- inferiority of the MenABCWY vaccine compared to the MenACWY vaccine in participants without a previous MenACWY vaccination (unprimed) as measured by the percentages of participants, achieving a 4- fold rise in hSBA titers against N. meningitidis serogroup W at 1 month after the last MenABCWY vaccination (Day 211) and 1 month after the MenACWY vaccination.

Comparison groups	ABCWY_Pooled v ACWY Group
Number of subjects included in analysis	1315
Analysis specification	Pre-specified
Analysis type	non-inferiority[23]
Parameter estimate	Difference in percentage of participants
Point estimate	35.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	26.88
upper limit	44.49

Notes:

[23] - Non-inferiority of MenABCWY vaccine is demonstrated if the LL of the 2-sided 95% CI for the difference in percentage of participants with 4-fold rise between the 2 groups is above -10%.

Statistical analysis title	Statistical Analysis 4

Statistical analysis description:

To demonstrate the immunological non- inferiority of the MenABCWY vaccine compared to the MenACWY vaccine in participants without a previous MenACWY vaccination (unprimed) as measured by the percentages of participants, achieving a 4- fold rise in hSBA titers against N. meningitidis serogroup Y at 1 month after the last MenABCWY vaccination (Day 211) and 1 month after the MenACWY vaccination.

Comparison groups	ABCWY_Pooled v ACWY Group

Number of subjects included in analysis	1315
Analysis specification	Pre-specified
Analysis type	non-inferiority[24]
Parameter estimate	Difference in percentage of participants
Point estimate	26.99
Confidence interval	
level	95 %
sides	2-sided
lower limit	19.38
upper limit	35.81

Notes:

[24] - Non-inferiority of MenABCWY vaccine is demonstrated if the LL of the 2-sided 95% CI for the difference in percentage of participants with 4-fold rise between the 2 groups is above -10%.

Statistical analysis title	Statistical Analysis 2

Statistical analysis description:

To demonstrate the immunological non- inferiority of the MenABCWY vaccine compared to the MenACWY vaccine in participants without a previous MenACWY vaccination (unprimed) as measured by the percentages of participants, achieving a 4- fold rise in hSBA titers against N. meningitidis serogroup C at 1 month after the last MenABCWY vaccination (Day 211) and 1 month after the MenACWY vaccination.

Comparison groups	ABCWY_Pooled v ACWY Group
Number of subjects included in analysis	1315
Analysis specification	Pre-specified
Analysis type	non-inferiority[25]
Parameter estimate	Difference in percentage of participants
Point estimate	47.22
Confidence interval	
level	95 %
sides	2-sided
lower limit	38.14
upper limit	56.3

Notes:

[25] - Non-inferiority of MenABCWY vaccine is demonstrated if the LL of the 2-sided 95% CI for the difference in percentage of participants with 4-fold rise between the 2 groups is above -10%.

Primary: Percentage of blood samples without bactericidal serum activity against each of the endemic U.S N. meningitidis serogroup B strains at 1 month after last MenABCWY vaccination (pooled lots) and MenACWY vaccination (for the ACWY Group)

End point title	Percentage of blood samples without bactericidal serum activity against each of the endemic U.S N. meningitidis serogroup B strains at 1 month after last MenABCWY vaccination (pooled lots) and MenACWY vaccination (for the ACWY Group)[26]

End point description:

The effectiveness (test-based) of 2 doses of MenABCWY vaccine when compared to 1 dose of MenACWY vaccine, against a panel of N. meningitidis serogroup B strains was measured in terms of percentage of samples without bactericidal activity using enc-hSBA, which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. As pre-specified in the protocol, data reported in this outcome measure were presented for ACWY group and ABCWY pooled group to evaluate the effectiveness of 2 doses of the MenABCWY vaccines against MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY- 3 groups were pooled into a single group. Analysis was performed on blood samples collected from PPS.

End point type	Primary

End point timeframe:

At 1 month after the vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 31 for the ACWY group)

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: As specified in the Protocol, the analysis assesses the effectiveness of the rMenB+OMV vaccine compared to one dose of MenACWY vaccination in the ACWY group.

End point values	ABCWY_Pooled	ACWY Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1356	147		
Units: Percentage of blood samples				
number (not applicable)				
Number of Blood samples analyzed (N=25715,4374)	17.4	79		

Statistical analyses

Statistical analysis title	Statistical analysis 1

Statistical analysis description:

To demonstrate the effectiveness of the MenABCWY vaccine against a randomly selected panel of endemic US N. meningitidis serogroup B invasive disease strains as measured by enc-hSBA at 1 month after the last MenABCWY vaccination (Day 211) when compared to 1 month after the MenACWY vaccination.

Comparison groups	ABCWY_Pooled v ACWY Group
Number of subjects included in analysis	1503
Analysis specification	Pre-specified
Analysis type	other[27]
Parameter estimate	VE
Point estimate	77.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	76.6
upper limit	79.2

Notes:

[27] - Effectiveness of MenABCWY vaccine is demonstrated if the LL of the 2-sided 95% CI for VE against the selected strain panel between the ABCWY and the ACWY groups is above 65%. VE is defined as 1- RR = (1- percentage of samples without bactericidal serum activity at 1:4 dilution in ABCWY_Pooled group / percentage of samples without bactericidal serum activity at 1:4 dilution in the ACWY group) x100 percentage.

Primary: Percentage of blood samples with bactericidal serum activity against each of the endemic U.S N. meningitidis serogroup B strains at 1 month after the last MenABCWY dose (pooled lots) and 2-dose(0,2-M) schedule of rMenB+OMV

End point title	Percentage of blood samples with bactericidal serum activity against each of the endemic U.S N. meningitidis serogroup B strains at 1 month after the last MenABCWY dose (pooled lots) and 2-dose(0,2-M) schedule of rMenB+OMV[28]

End point description:

The effectiveness was measured in terms of percentage of samples with bactericidal activity using enc-hSBA, which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 Group and ABCWY pooled group to evaluate the effectiveness of 2 doses of the MenABCWY vaccines against MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. Analysis was performed on blood samples collected from PPS, which included participants who

received at least 1 dose of the study treatment to which they were randomized and have post-vaccination data for the specified analysis at specified timepoints and did not have any protocol deviations that lead to exclusion from the PPS.

End point type	Primary

End point timeframe:

At 1 month after the vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 91 for the MenB_0_2_6 Group [2-dose schedule])

Notes:

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: As specified in the Protocol, the analysis assesses the effectiveness of the MenABCWY vaccine compared to the rMenB+OMV vaccine in terms of the percentage of samples with bactericidal serum activity.

End point values	MenB_0_2_6 Group	ABCWY_Pooled		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	740	1356		
Units: Percentage of blood samples				
number (not applicable)				
Number of Blood samples Analyzed (27569, 25715)	83.1	82.5		

Statistical analyses

Statistical analysis title	Statistical analysis 1

Statistical analysis description:

To demonstrate the non-inferiority of the effectiveness of the MenABCWY vaccine (0,6-months schedule) compared to the rMenB+OMV NZ vaccine (0,2-months) in terms of percentage of samples with bactericidal serum activity using enc-hSBA against a randomly selected panel of endemic US N. meningitidis serogroup B invasive disease strains.

Comparison groups	MenB_0_2_6 Group v ABCWY_Pooled
Number of subjects included in analysis	2096
Analysis specification	Pre-specified
Analysis type	non-inferiority[29]
Parameter estimate	Difference in percentage of participants
Point estimate	-0.61
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.25
upper limit	0.03

Notes:

[29] - Non-inferiority of MenABCWY to rMenB+OMV NZ is demonstrated if LL of the 2-sided 95% CI for the difference in percentages of samples with bactericidal serum activity at 1:4 dilution is above -5%.

Primary: Percentage of participants whose sera kill >=70% of the strains tested using enc-hSBA at 1 month after the last vaccination in the ABCWY Group (pooled lots)

End point title	Percentage of participants whose sera kill >=70% of the strains tested using enc-hSBA at 1 month after the last vaccination in the ABCWY Group (pooled lots)[30][31]

End point description:

The effectiveness (responder-based) of the MenABCWY vaccine is measured in terms of percentage of participants whose sera kill >=70% of the strains tested using enc-hSBA, being calculated based on Clopper Pearson method. Effectiveness is demonstrated Lower Limit (LL) of the two-sided 97.5% CI for the percentages of subjects whose sera kill ≥70% of strains tested for MenABCWY is above 65%. Analysis was performed on the FAS.

End point type	Primary

End point timeframe:

At 1 month after the last vaccination of MenABCWY (Day 211)

Notes:

[30] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.
[31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: As specified in the Protocol, the analysis assesses the effectiveness of the MenABCWY vaccine.

End point values	ABCWY_Pooled			
Subject group type	Reporting group			
Number of subjects analysed	817			
Units: Percentage of participants				
number (confidence interval 95%)	84.1 (81.4 to 86.5)			

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with any solicited local adverse events (AEs) after the first study intervention administration

End point title	Number of participants with any solicited local adverse events (AEs) after the first study intervention administration[32]

End point description:

Assessed solicited local adverse events were injection or administration site pain, erythema, swelling, induration. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group. Analysis was performed on the Solicited Safety Set (SSS).

End point type	Primary

End point timeframe:

During 7 days after the first study intervention administration occurring at Day 1

Notes:

[32] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	MenB_0_2_6 Group	MenB_0_6 Group	ABCWY_Pooled	ACWY Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	885	894	1638	178
Units: participants				
Pain	807	819	1503	67
Erythema	90	86	216	11
Swelling	87	89	217	11
Induration	60	64	150	7

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with any solicited local adverse events (AEs) after the second study intervention administration

End point title	Number of participants with any solicited local adverse events (AEs) after the second study intervention administration[33]

End point description:

Assessed solicited local adverse events were injection or administration site pain, erythema, swelling, induration. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group. Analysis was performed on the Solicited Safety Set (SSS).

End point type	Primary

End point timeframe:

During 7 days after the second study intervention administration occurring at Day 61

Notes:

[33] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	MenB_0_2_6 Group	MenB_0_6 Group	ABCWY_Pooled	ACWY Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	823	813	1511	161
Units: participants				
Pain	714	224	205	30
Erythema	89	26	5	1
Swelling	99	22	5	1
Induration	67	19	6	0

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with any solicited local adverse events (AEs) after

the third study intervention administration

End point title	Number of participants with any solicited local adverse events (AEs) after the third study intervention administration[34]

End point description:

Assessed solicited local adverse events were injection site pain, erythema, swelling, induration. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group. Analysis was performed on the Solicited Safety Set (SSS).

End point type	Primary

End point timeframe:

During 7 days after the third study intervention administration occurring at Day 181

Notes:

[34] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	MenB_0_2_6 Group	MenB_0_6 Group	ABCWY_Pooled	ACWY Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	765	759	1428	148
Units: participants				
Pain	677	676	1258	126
Erythema	118	87	168	11
Swelling	107	85	176	13
Induration	52	57	114	12

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with any solicited systemic AEs after the first study intervention administration

End point title	Number of participants with any solicited systemic AEs after the first study intervention administration[35]

End point description:

Assessed solicited systemic AEs were fatigue, nausea, myalgia, arthralgia, headache and fever [temperature >= 38.0°C]. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group. Analysis was performed on the Solicited Safety Set (SSS).

End point type	Primary

End point timeframe:

During 7 days after the first study intervention administration occurring at Day 1

Notes:

[35] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	MenB_0_2_6 Group	MenB_0_6 Group	ABCWY_Pooled	ACWY Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	885	894	1638	178
Units: participants				
Fatigue	423	414	828	78
Nausea	112	111	242	27
Myalgia	92	106	242	13
Arthralgia	56	70	133	17
Headache	358	330	681	69
Fever (C)	19	17	55	3

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with any solicited systemic AEs after the second study intervention administration

End point title	Number of participants with any solicited systemic AEs after the second study intervention administration[36]

End point description:

Assessed solicited systemic AEs were fatigue, nausea, myalgia, arthralgia, headache and fever [temperature >= 38.0°C]. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group. Analysis was performed on the Solicited Safety Set (SSS).

End point type	Primary

End point timeframe:

During 7 days after the second study intervention administration occurring at Day 61

Notes:

[36] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	MenB_0_2_6 Group	MenB_0_6 Group	ABCWY_Pooled	ACWY Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	823	813	1511	161
Units: participants				
Fatigue	372	228	345	36
Nausea	104	56	85	18
Myalgia	110	46	55	3
Arthralgia	72	332	35	6
Headache	301	223	332	31
Fever (C)	22	12	18	1

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with any solicited systemic AEs after the third study intervention administration

End point title	Number of participants with any solicited systemic AEs after the third study intervention administration[37]

End point description:

Assessed solicited systemic AEs were fatigue, nausea, myalgia, arthralgia, headache and fever [temperature >= 38.0°C]. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group. Analysis was performed on the Solicited Safety Set (SSS).

End point type	Primary

End point timeframe:

During 7 days after the third study intervention administration occurring at Day 181

Notes:

[37] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	MenB_0_2_6 Group	MenB_0_6 Group	ABCWY_Pooled	ACWY Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	765	759	1428	148
Units: participants				
Fatigue	374	341	602	56
Nausea	94	84	147	14
Myalgia	106	109	168	17
Arthralgia	71	53	104	7
Headache	302	284	509	39
Fever (C)	21	23	27	2

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with any unsolicited AEs after the first study intervention administration

End point title	Number of participants with any unsolicited AEs after the first study intervention administration[38]

End point description:

Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms were reported as an unsolicited AE. Any Unsolicited AEs (including Serious adverse events (SAEs), AEs leading to withdrawal, Adverse event of special interest (AESIs) and medically attended AEs were collected during 30 days after vaccination 1-3. For vaccination on Day 211 (Vaccination 4), conducted as part of standard of care and to maintain blinding, no eDiary data or all unsolicited AEs were collected for the 30 days following vaccination. However, SAEs, AEs leading to withdrawal, AESIs and medically attended AEs were collected throughout study duration. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group. Analysis was performed on the Unsolicited Safety Set (USS).

End point type	Primary

End point timeframe:

During the 30 days after the first study intervention administration occurring at Day 1

Notes:

[38] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	MenB_0_2_6 Group	MenB_0_6 Group	ABCWY_Pooled	ACWY Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	893	900	1648	178
Units: participants	90	124	217	29

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with any unsolicited AEs after the second study intervention administration

End point title	Number of participants with any unsolicited AEs after the second study intervention administration[39]

End point description:

Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms were reported as an unsolicited AE. Any Unsolicited AEs (including Serious adverse events (SAEs), AEs leading to withdrawal, Adverse event of special interest (AESIs) and medically attended AEs were collected during 30 days after vaccination 1-3. For vaccination on Day 211 (Vaccination 4), conducted as part of standard of care and to maintain blinding, no eDiary data or all unsolicited AEs were collected for the 30 days following vaccination. However, SAEs, AEs leading to withdrawal, AESIs and medically attended AEs were collected throughout study duration. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group. Analysis was performed on the Unsolicited Safety Set (USS).

End point type	Primary

End point timeframe:

During the 30 days after the second study intervention administration occurring at Day 61

Notes:

[39] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	MenB_0_2_6 Group	MenB_0_6 Group	ABCWY_Pooled	ACWY Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	851	855	1579	170
Units: participants	106	88	160	15

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with any unsolicited AEs after the third study intervention administration

End point title	Number of participants with any unsolicited AEs after the third study intervention administration[40]

End point description:

Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms were reported as an unsolicited AE. Any Unsolicited AEs (including Serious adverse events (SAEs), AEs leading to withdrawal, Adverse event of special interest (AESIs) and medically attended AEs were collected during 30 days after vaccination 1-3. For vaccination on Day 211 (Vaccination 4), conducted as part of standard of care and to maintain blinding, no eDiary data or all unsolicited AEs were collected for the 30 days following vaccination. However, SAEs, AEs leading to withdrawal, AESIs and medically attended AEs were collected throughout study duration. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group. Analysis was performed on the Unsolicited Safety Set (USS).

End point type	Primary

End point timeframe:

During the 30 days after the third study intervention administration occurring at Day 181

Notes:

[40] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	MenB_0_2_6 Group	MenB_0_6 Group	ABCWY_Pooled	ACWY Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	815	823	1521	166
Units: participants	96	94	183	19

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with SAEs, AEs leading to withdrawal, AESIs and medically attended AEs

End point title	Number of participants with SAEs, AEs leading to withdrawal, AESIs and medically attended AEs[41]

End point description:

A SAEs is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity and is a congenital anomaly/birth defect in the offspring of a study subject. AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation to characterize and understand it. Medically attended AEs are symptoms or illnesses requiring hospitalization, or emergency room visit, or visit to/by a health care provider. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group. Analysis was performed on the Unsolicited Safety Set (USS).

End point type	Primary

End point timeframe:

Throughout the study period (Day 1 to Day 361)

Notes:

[41] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: The analysis of this primary endpoint was descriptive i.e. no statistical hypothesis test was performed.

End point values	MenB_0_2_6 Group	MenB_0_6 Group	ABCWY_Pooled	ACWY Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	893	900	1648	178
Units: participants				
SAEs	20	22	25	5
AEs leading to withdrawal	6	4	4	1
AESIs	1	1	6	0
medically attended AEs	238	288	479	44

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of blood samples without bactericidal serum activity against each of the endemic U.S N. meningitidis serogroup B strains at 1 month after the last MenABCWY dose and 3-dose (0,2,6-M), 2-dose(0,6-M) schedule of rMenB+OMV and 1 dose of MenACWY

End point title	Percentage of blood samples without bactericidal serum activity against each of the endemic U.S N. meningitidis serogroup B strains at 1 month after the last MenABCWY dose and 3-dose (0,2,6-M), 2-dose(0,6-M) schedule of rMenB+OMV and 1 dose of MenACWY

End point description:

The effectiveness of the 3 dose (0,2,6-M) and 2 dose (0,6-M) schedule of rMenB+OMV NZ vaccine and 2 doses of MenABCWY vaccine when compared to 1 month after the MenACWY vaccination (Day 31), against a panel of N. meningitidis serogroup B strains is measured in terms of percentage of samples without bactericidal activity using enc-hSBA, which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. Participants were randomly selected for testing against each strain therefore only a subset of participants were tested for each of the strains. Number of Participants analyzed = Total number of participants included in FAS. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group,ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

End point type	Secondary

End point timeframe:

At 1 month after the vaccination schedule (i.e., Day 211 for the MenB_0_2_6 group [3 dose schedule], MenB_0_6 group, ABCWY_Pooled group and Day 31 for the MenACWY group)

End point values	MenB_0_2_6 Group	MenB_0_6 Group	ABCWY_Pooled	ACWY Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	790	813	817	136
Units: Percentage of blood samples				
number (not applicable)				
Meningitis B M10713 Ab (N= 252,247,251,45)	0.4	0.4	1.2	15.6
Meningitis B M08641 Ab (N= 229,259,237,29)	6.6	6.2	8	96.6
Meningitis B M12898 Ab (N= 242,265,249,41)	8.4	11.4	12.1	68.1
Meningitis B M09150 Ab (N= 249,222,273,36)	5.2	8.5	12.6	73

Meningitis B M09401 Ab (N= 243,275,288,49)	50.2	46.5	57	98
Meningitis B M07463 Ab (N= 259,274,256,49)	1.5	1.8	3.5	49
Meningitis B M10496 Ab (N= 263,261,257,47)	54.4	47.9	68.9	100
Meningitis B M14530 Ab (N= 241,257,284,37)	2.1	1.6	3.2	100
Meningitis B M15668 Ab (N= 237,270,262,49)	0.8	2.2	0.8	87.8
Meningitis B M14028 Ab (N= 246,282,283,37)	2.8	5.7	4.9	100
Meningitis B M09909 Ab (N= 244,265,261,42)	79.1	83.4	86.2	100
Meningitis B M14385 Ab (N= 235,237,259,43)	0.9	0.8	0	16.3
Meningitis B M07992 Ab (N= 237,252,274,36)	0.4	0	0.4	0
Meningitis B M09155 Ab (N= 234,255,230,45)	1.7	2	1.3	97.8
Meningitis B M13085 Ab (N= 256,253,255,44)	13.5	27.5	26.6	69.3
Meningitis B M18303 Ab (N= 241,252,264,40)	2.9	4	9.5	100
Meningitis B M18711 Ab (N= 252,237,262,33)	5.2	4.2	9.5	75.8
Meningitis B M15009 Ab (N= 262,254,242,37)	11.8	20.5	31.8	86.5
Meningitis B M07773 Ab (N= 269,262,251,35)	0.7	0.4	0.4	74.3
Meningitis B M09662 Ab (N= 267,266,255,48)	61.4	50.8	66.3	95.8
Meningitis B M18483 Ab (N= 228,233,222,37)	3	5.1	3.7	72.2
Meningitis B M11906 Ab (N= 264,271,260,39)	23.7	30.3	39.9	84.7
Meningitis B M14987 Ab (N= 250,274,270,35)	1.2	8.8	12.7	68.6
Meningitis B M12014 Ab (N= 249,270,254,46)	0.4	0.7	1.2	67.4
Meningitis B M18200 Ab (N= 228,247,242,47)	6.3	14.8	14.9	33.7
Meningitis B M08912 Ab (N= 225,247,237,40)	0.4	0	0	0
Meningitis B M16748 Ab (N= 262,252,260,45)	0.8	0	0	0
Meningitis B M08152 Ab (N= 208,215,223,35)	22.4	25.3	32.8	66.8
Meningitis B M09973 Ab (N= 252,270,247,48)	0.8	1.1	3	83.3
Meningitis B M15352 Ab (N= 237,249,245,33)	8.9	8.4	17.8	97
Meningitis B M15165 Ab (N= 249,250,240,42)	0	1.2	2.1	92.9
Meningitis B M08127 Ab (N= 269,250,287,51)	0.7	0.4	0.7	84.3
Meningitis B M18347 Ab (N= 234,262,239,44)	45.4	50.9	51.8	82.1
Meningitis B M12500 Ab (N= 223,253,241,43)	0.9	2.4	2.5	95.3
Meningitis B M07499 Ab (N= 242,251,256,51)	70.7	75.7	80.1	100

Meningitis B M09960 Ab (N= 243,247,251,33)	1.2	0	0	3
Meningitis B M18045 Ab (N= 236,251,272,41)	0	0.4	0	92.7
Meningitis B M10548 Ab (N= 234,243,261,58)	8.1	11.9	12.5	74.1
Meningitis B M09354 Ab (N= 246,240,241,40)	1.2	1.3	0	80
Meningitis B M11051 Ab (N= 246,282,247,46)	61	64.2	66.7	97.8
Meningitis B M10104 Ab (N= 247,241,239,41)	58.7	52.3	63.5	97.6
Meningitis B M13361 Ab (N= 258,268,250,34)	0.8	0.4	0.4	85.3
Meningitis B M11042 Ab (N= 217,249,254,43)	19.8	25.5	33.5	85.7
Meningitis B M18467 Ab (N= 255,223,250,47)	1.2	0.4	0.8	78.7
Meningitis B M11113 Ab (N= 255,253,269,51)	30.1	39.5	49.5	75.2
Meningitis B M07253 Ab (N= 260,245,255,40)	34.7	33.8	50.2	86.4
Meningitis B M07356 Ab (N= 235,235,266,29)	0.4	0	1.1	41.4
Meningitis B M10710 Ab (N= 254,253,270,40)	1.6	2	1.4	92.5
Meningitis B M17147 Ab (N= 261,279,214,41)	2.3	5.4	2.3	100
Meningitis B M14401 Ab (N= 241,266,253,43)	1.7	0.4	1.2	83.7
Meningitis B M14293 Ab (N= 251,247,224,47)	45.8	25.1	45.2	95.7
Meningitis B M08540 Ab (N= 258,261,222,34)	1.6	0.8	0	38.2
Meningitis B M07960 Ab (N= 277,241,241,39)	3.6	4.1	1.8	94.9
Meningitis B M16135 Ab (N= 254,230,257,41)	0	1.7	0.8	95.1
Meningitis B M14548 Ab (N= 267,266,274,38)	2.6	3.4	3.2	94.7
Meningitis B M09181 Ab (N= 228,276,240,43)	0	0.4	0.4	72.1
Meningitis B M14224 Ab (N= 248,279,277,40)	0.4	0.4	0	82.5
Meningitis B M07452 Ab (N= 260,260,245,47)	2.7	8.1	17.1	85.1
Meningitis B M13520 Ab (N= 217,222,242,30)	3.2	0.9	0	66.7
Meningitis B M09385 Ab (N= 228,252,265,32)	0.4	1.6	0	46.9
Meningitis B M14881 Ab (N= 240,278,277,40)	4.2	5.8	10	95
Meningitis B M13252 Ab (N= 279,241,262,50)	0.7	1.2	0.4	98
Meningitis B M07818 Ab (N= 232,244,228,43)	0.4	0.8	1.3	90.7
Meningitis B M09914 Ab (N= 281,257,258,49)	85.4	86.8	88.3	98
Meningitis B M15083 Ab (N= 231,262,241,40)	51.4	56.7	61	84.5
Meningitis B M11290 Ab (N= 264,266,221,34)	61.4	61.7	67.4	100

Meningitis B M14988 Ab (N= 241,269,246,40)	0.4	0	1.2	60
Meningitis B M10536 Ab (N= 228,223,260,36)	19.7	14.3	14.3	91.7
Meningitis B M08959 Ab (N= 252,241,258,47)	0.8	0.4	1.9	85.1
Meningitis B M08785 Ab (N= 251,249,260,39)	0.8	0.4	0.4	53.8
Meningitis B M07245 Ab (N= 238,248,230,43)	0	0	0.9	23.3
Meningitis B M19315 Ab (N= 262,254,255,34)	3.8	3.1	9.5	79.4
Meningitis B M14376 Ab (N= 234,220,222,41)	0	1.4	0	92.7
Meningitis B M08994 Ab (N= 226,253,233,31)	2.5	7.6	6.9	62.7
Meningitis B M11646 Ab (N= 241,224,250,36)	0	1.3	2	83.3
Meningitis B M13362 Ab (N= 259,228,231,49)	0	0.4	0.4	81.6
Meningitis B M08080 Ab (N= 236,247,242,45)	27.4	41	51.6	85.7
Meningitis B M08370 Ab (N= 265,262,251,43)	2.3	1.5	3.7	97.7
Meningitis B M08129 Ab (N= 245,254,257,28)	4.1	4.7	7	71.4
Meningitis B M07111 Ab (N= 231,254,270,33)	0.4	1.2	0.7	90.9
Meningitis B M07537 Ab (N= 241,242,263,47)	95.9	95.9	97.7	100
Meningitis B M13438 Ab (N= 255,262,282,50)	1.2	0.8	0	16
Meningitis B M10661 Ab (N= 246,275,273,33)	2	2.9	2.9	97
Meningitis B M10920 Ab (N= 247,252,275,34)	29.1	27.8	37.8	91.2
Meningitis B M15564 Ab (N= 240,273,263,40)	0.4	0.7	0.8	77.5
Meningitis B M10934 Ab (N= 273,241,256,36)	0.4	0.8	0.8	100
Meningitis B M09400 Ab (N= 254,281,279,39)	0.8	1.8	0.4	97.4
Meningitis B M08781 Ab (N= 221,258,229,28)	71.9	74.4	78.2	100
Meningitis B M09173 Ab (N= 238,249,247,42)	0.4	0.4	0.8	95.2
Meningitis B M14113 Ab (N= 228,255,264,42)	15.4	21.2	22	100
Meningitis B M08389 Ab (N= 254,259,250,45)	10.7	7	11.7	87.2
Meningitis B M16822 Ab (N= 239,233,264,34)	67.8	76.4	82.2	100
Meningitis B M10995 Ab (N= 268,258,239,47)	5.2	17.8	30.6	85.1
Meningitis B M08780 Ab (N= 236,259,260,40)	1.3	0.8	1.5	92.5
Meningitis B M09910 Ab (N= 247,246,257,43)	1.6	1.2	1.2	93
Meningitis B M08320 Ab (N= 262,238,253,45)	33.6	39.7	43.3	87
Meningitis B M14879 Ab (N= 239,242,247,47)	2.1	2.1	6.1	21.3

Meningitis B M09345 Ab (N= 251,257,282,48)	19.3	20.1	33.4	81.2
Meningitis B M14594 Ab (N= 245,241,238,44)	20.8	27.4	41.2	97.7
Meningitis B M07621 Ab (N= 251,260,263,40)	1.2	1.2	1.1	77.5
Meningitis B M13568 Ab (N= 261,264,253,40)	5.4	3.8	3.9	95
Meningitis B M18017 Ab (N= 246,247,258,31)	0.4	0	1.6	96.8
Meningitis B M08420 Ab (N= 243,255,256,40)	0.8	0.4	1.6	95
Meningitis B M07959 Ab (N= 236,237,254,35)	1.7	2.5	1.7	97.1
Meningitis B M06970 Ab (N= 236,261,253,32)	19.6	17.6	30.2	85.7
Meningitis B M10491 Ab (N= 239,262,227,39)	5.4	8.4	17	82.1
Meningitis B M13569 Ab (N= 221,243,247,31)	0.9	2.9	1.2	96.8
Meningitis B M10182 Ab (N= 229,234,256,44)	0.4	0	0	0
Meningitis B M13547 Ab (N= 251,258,238,44)	2.4	7	4.7	47.7
Meningitis B M15276 Ab (N= 231,231,259,41)	0.4	0	1.5	87.8

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with 4-fold rise in hSBA titers against N.meningitidis group B strains at 1 month after last MenABCWY dose (ABCWY group-pooled lots) and 1 month afte 2-dose(0,2-M) schedule of rMenB+OMV NZ relative to baseline

End point title	Percentage of participants with 4-fold rise in hSBA titers against N.meningitidis group B strains at 1 month after last MenABCWY dose (ABCWY group-pooled lots) and 1 month afte 2-dose(0,2-M) schedule of rMenB+OMV NZ relative to baseline[42]

End point description:

The immunogenicity is measured as percentage of participants achieving a 4-fold rise in hSBA titers against N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively). 4-fold rise per each indicator strain was defined as a post-vaccination hSBA titre ≥16 for participants with a pre-vaccination hSBA titre <4; a post-vaccination hSBA titre ≥4 times the LLOQ for participants with a pre-vaccination hSBA titre ≥LOD and <LLOQ; a post-vaccination hSBA titre ≥4 times the pre-vaccination hSBA titre for participants with a pre-vaccination hSBA titre ≥ LLOQ. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 Group and ABCWY pooled group to evaluate the effectiveness of 2 doses of the MenABCWY vaccines against MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. The analysis was performed on the PPS.

End point type	Secondary

End point timeframe:

At 1 month after the vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 91 for the MenB_0_2_6 Group [2-dose schedule]) compared to Day 1 (Baseline)

Notes:

[42] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: As specified in the Protocol, the analysis assesses the immunological noninferiority of the MenABCWY vaccine compared to the rMenB+OMV vaccine.

End point values	MenB_0_2_6 Group	ABCWY_Pooled		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	719	678		
Units: Percentage of participants				
number (confidence interval 95%)				
fHbp (M14459) Ab (N=719,675)	74.7 (71.3 to 77.8)	79.7 (76.5 to 82.7)		
NadA (96217) Ab (N=717,671)	96.4 (94.7 to 97.6)	92.7 (90.5 to 94.5)		
NHBA (M13520) Ab (N=718,678)	58.6 (54.9 to 62.3)	61.9 (58.2 to 65.6)		
PorA (NZ98/254) Ab (N=704,642)	53.3 (49.5 to 57.0)	42.2 (38.4 to 46.1)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of blood samples without bactericidal serum activity using enc-hSBA against each of the endemic U.S N. meningitidis serogroup B strains at 1 month after the 2-dose(0,6-M) schedule of rMenB+OMV and 1 dose of MenACWY

End point title	Percentage of blood samples without bactericidal serum activity using enc-hSBA against each of the endemic U.S N. meningitidis serogroup B strains at 1 month after the 2-dose(0,6-M) schedule of rMenB+OMV and 1 dose of

End point description:

The effectiveness of the 2 dose (0,2-M) schedule of rMenB+OMV NZ vaccine when compared to 1 month after the MenACWY vaccination (Day 31), against a panel of N. meningitidis serogroup B strains is measured in terms of percentage of samples without bactericidal activity using enc-hSBA, which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4.
Participants were randomly selected for testing against each strain therefore only a subset of participants were tested for each of the strains. Number of Participants analyzed = Total number of participants included in FAS.
Analysis was performed on blood samples collected from FAS.

End point type	Secondary

End point timeframe:

At 1 month after the vaccination schedule (i.e., Day 91 for the MenB_0_2_6 group [2 dose schedule] and Day 31 for the MenACWY group)

Notes:

[43] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: As specified in the Protocol, the analysis assesses the effectiveness of the rMenB+OMV vaccine compared to one dose of MenACWY vaccination in the ACWY group.

End point values	MenB_0_2_6 Group	ACWY Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	893	173		
Units: Percentage of blood samples				
number (not applicable)				
Meningitis B M10713 Ab (N=266,45)	1.9	15.6		
Meningitis B M08641 Ab (N=250,29)	11.2	96.6		
Meningitis B M12898 Ab (N=260,41)	12.4	69		
Meningitis B M09150 Ab (N=250,36)	9.3	68.6		
Meningitis B M09401 Ab (N=253,49)	47	98		
Meningitis B M07463 Ab (N=265,49)	2.6	49		
Meningitis B M10496 Ab (N=277,47)	50.5	100		
Meningitis B M14530 Ab (N=254,37)	3.9	100		
Meningitis B M15668 Ab (N=252,49)	0.4	87.8		
Meningitis B M14028 Ab (N=257,37)	5.4	100		
Meningitis B M09909 Ab (N=266,42)	82	100		
Meningitis B M14385 Ab (N=227,43)	0	16.3		
Meningitis B M07992 Ab (N=249,36)	0	0		
Meningitis B M09155 Ab (N=243,45)	2.5	97.8		
Meningitis B M13085 Ab (N=271,44)	21	66.4		
Meningitis B M18303 Ab (N=252,40)	9.1	100		
Meningitis B M18711 Ab (N=261,33)	7.7	75.8		
Meningitis B M15009 Ab (N=243,37)	22.2	86.5		
Meningitis B M07773 Ab (N=281,35)	1.1	74.3		
Meningitis B M09662 Ab (N=284,48)	58.1	95.8		
Meningitis B M18483 Ab (N=234,37)	4.3	77.3		
Meningitis B M11906 Ab (N=277,39)	38.8	85.3		
Meningitis B M14987 Ab (N=264,35)	10.7	62.3		
Meningitis B M12014 Ab (N=267,46)	0.7	63.2		
Meningitis B M18200 Ab (N=241,47)	12.1	34.4		
Meningitis B M08912 Ab (N=246,40)	0	0		
Meningitis B M16748 Ab (N=281,45)	0	0		
Meningitis B M08152 Ab (N=224,35)	35.6	67.2		
Meningitis B M09973 Ab (N=271,48)	1.5	83.3		
Meningitis B M15352 Ab (N=219,33)	11.9	97		
Meningitis B M15165 Ab (N=265,42)	0.8	92.9		
Meningitis B M08127 Ab (N=285,51)	0.4	84.3		
Meningitis B M18347 Ab (N=249,44)	60.5	80.4		
Meningitis B M12500 Ab (N=236,43)	3.4	95.3		
Meningitis B M07499 Ab (N=259,51)	81.1	100		
Meningitis B M09960 Ab (N=251,33)	4.4	3		
Meningitis B M18045 Ab (N=247,41)	0	92.7		
Meningitis B M10548 Ab (N=244,58)	11.9	74.1		
Meningitis B M09354 Ab (N=258,40)	0.4	80		
Meningitis B M11051 Ab (N=270,46)	68.9	97.8		
Meningitis B M10104 Ab (N=249,41)	61.8	97.6		
Meningitis B M13361 Ab (N=269,34)	0.4	85.3		
Meningitis B M11042 Ab (N=210,43)	30.1	84.2		
Meningitis B M18467 Ab (N=272,47)	0.4	78.7		
Meningitis B M11113 Ab (N=273,51)	43.1	75.6		
Meningitis B M07253 Ab (N=274,40)	43.3	85.3		

Meningitis B M07356 Ab (N=247,29)	0	41.4		
Meningitis B M10710 Ab (N=269,40)	2.2	92.5		
Meningitis B M17147 Ab (N=274,41)	5.1	100		
Meningitis B M14401 Ab (N=251,43)	0.8	83.7		
Meningitis B M14293 Ab (N=264,47)	36.4	95.7		
Meningitis B M08540 Ab (N=271,34)	0.4	38.2		
Meningitis B M07960 Ab (N=292,39)	4.1	94.9		
Meningitis B M16135 Ab (N=263,41)	0.8	95.1		
Meningitis B M14548 Ab (N=286,38)	2.8	94.7		
Meningitis B M09181 Ab (N=252,43)	0	72.1		
Meningitis B M14224 Ab (N=268,40)	0.7	82.5		
Meningitis B M07452 Ab (N=267,47)	13.5	85.1		
Meningitis B M13520 Ab (N=234,30)	0.9	66.7		
Meningitis B M09385 Ab (N=230,32)	2.2	46.9		
Meningitis B M14881 Ab (N=258,40)	14.7	95		
Meningitis B M13252 Ab (N=286,50)	3.1	98		
Meningitis B M07818 Ab (N=249,43)	0.4	90.7		
Meningitis B M09914 Ab (N=293,49)	87.7	98		
Meningitis B M15083 Ab (N=260,40)	63.7	78		
Meningitis B M11290 Ab (N=278,34)	70.5	100		
Meningitis B M14988 Ab (N=251,40)	0.4	60		
Meningitis B M10536 Ab (N=241,36)	23.2	91.7		
Meningitis B M08959 Ab (N=267,47)	0.4	85.1		
Meningitis B M08785 Ab (N=262,39)	0.4	53.8		
Meningitis B M07245 Ab (N=254,43)	0	23.3		
Meningitis B M19315 Ab (N=270,34)	6.3	79.4		
Meningitis B M14376 Ab (N=269,41)	0	92.7		
Meningitis B M08994 Ab (N=233,31)	8.9	55.7		
Meningitis B M11646 Ab (N=252,36)	1.6	83.3		
Meningitis B M13362 Ab (N=272,49)	1.5	81.6		
Meningitis B M08080 Ab (N=244,45)	46.8	87.1		
Meningitis B M08370 Ab (N=280,43)	3.9	97.7		
Meningitis B M08129 Ab (N=242,28)	7.4	71.4		
Meningitis B M07111 Ab (N=244,33)	0.4	90.9		
Meningitis B M07537 Ab (N=253,47)	96.4	100		
Meningitis B M13438 Ab (N=263,50)	0.4	16		
Meningitis B M10661 Ab (N=259,33)	2.7	97		
Meningitis B M10920 Ab (N=259,34)	50.2	91.2		
Meningitis B M15564 Ab (N=258,40)	0.8	77.5		
Meningitis B M10934 Ab (N=286,36)	0	100		
Meningitis B M09400 Ab (N=261,39)	1.1	97.4		
Meningitis B M08781 Ab (N=223,28)	75.8	100		
Meningitis B M09173 Ab (N=244,42)	0	95.2		
Meningitis B M14113 Ab (N=244,42)	28.3	100		
Meningitis B M08389 Ab (N=258,45)	1.9	86.7		
Meningitis B M16822 Ab (N=240,34)	85	100		
Meningitis B M10995 Ab (N=282,47)	16.3	85.1		
Meningitis B M08780 Ab (N=241,40)	0.8	92.5		
Meningitis B M09910 Ab (N=256,43)	1.2	93		
Meningitis B M08320 Ab (N=277,45)	45.1	86.8		
Meningitis B M14879 Ab (N=252,47)	3.3	23.2		
Meningitis B M09345 Ab (N=263,48)	32.3	74.9		

Meningitis B M14594 Ab (N=254,44)	35.8	97.7		
Meningitis B M07621 Ab (N=259,40)	0.4	77.5		
Meningitis B M13568 Ab (N=268,40)	9.7	95		
Meningitis B M18017 Ab (N=262,31)	0	96.8		
Meningitis B M08420 Ab (N=260,40)	0.8	95		
Meningitis B M07959 Ab (N=243,35)	1.2	97.1		
Meningitis B M06970 Ab (N=243,32)	28.8	90.6		
Meningitis B M10491 Ab (N=254,39)	16.1	82.1		
Meningitis B M13569 Ab (N=233,31)	0.4	96.8		
Meningitis B M10182 Ab (N=251,44)	0	0		
Meningitis B M13547 Ab (N=260,44)	5	47.7		
Meningitis B M15276 Ab (N=238,41)	0.4	87.8		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants classified by percentage of serogroup B invasive disease strains killed using enc-hSBA in each subject at 1 month after vaccination schedule for the MenB_0_2_6 group [3 dose], MenB_0_6 group and last MenABCWY dose (pooled lots)

End point title	Percentage of participants classified by percentage of serogroup B invasive disease strains killed using enc-hSBA in each subject at 1 month after vaccination schedule for the MenB_0_2_6 group [3 dose], MenB_0_6 group and last MenABCWY dose (pooled lots)[44]

End point description:

The percentage of participants classified by percentage of N.meningitidis serogroup B invasive strains killed using enc-hSBA and the corresponding 2- sided 95% CI based on Clopper-Pearson method is calculated for each vaccine group. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. Analysis was performed on the FAS.

End point type	Secondary

End point timeframe:

At 1 month after the vaccination schedule (Day 211 for MenB_0_2_6 group (3 dose schedule), MenB_0_6 group and ABCWY_Pooled group)

Notes:

[44] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: As specified in the Protocol, the analysis assesses the percentage of serogroup B invasive disease strains killed within a subject using enc-hSBA of the rMenB+OMV and MenABCWY vaccines.

End point values	MenB_0_2_6 Group	MenB_0_6 Group	ABCWY_Pooled	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	790	813	817	
Units: Percentage of participants				
number (confidence interval 95%)				
>=50% killed strains	98.7 (97.7 to 99.4)	98.5 (97.4 to 99.2)	98 (96.8 to 98.9)	
>=55% killed strains	98.4 (97.2 to 99.1)	97.4 (96.1 to 98.4)	96.8 (95.4 to 97.9)	

>=60% killed strains	97.8 (96.6 to 98.7)	96.8 (95.3 to 97.9)	95.2 (93.5 to 96.6)	
>=65% killed strains	96.5 (94.9 to 97.6)	93.6 (91.7 to 95.2)	90.1 (87.8 to 92)	
>=70% killed strains	93.4 (91.5 to 95)	89.8 (87.5 to 91.8)	84.1 (81.4 to 86.5)	
>=75% killed strains	86.8 (84.3 to 89.1)	82.2 (79.4 to 84.7)	74.7 (71.5 to 77.6)	
>=80% killed strains	79.2 (76.2 to 82)	75.5 (72.4 to 78.4)	66 (62.6 to 69.2)	
>=85% killed strains	62.8 (59.3 to 66.2)	60.4 (56.9 to 63.8)	50.1 (46.6 to 53.5)	
>=90% killed strains	43.7 (40.2 to 47.2)	41.3 (37.9 to 44.8)	32.1 (28.9 to 35.4)	
>=95% killed strains	22.5 (19.7 to 25.6)	21 (18.3 to 24)	13.7 (11.4 to 16.3)	
100% killed strains	10 (8 to 12.3)	8.4 (6.6 to 10.5)	6.1 (4.6 to 8)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants classified by percentage of serogroup B invasive disease strains killed using enc-hSBA in each subject at 1 month after vaccination with rMenB+OMV NZ (0,2-months)

End point title	Percentage of participants classified by percentage of serogroup B invasive disease strains killed using enc-hSBA in each subject at 1 month after vaccination with rMenB+OMV NZ (0,2-months)[45]

End point description:

The percentage of participants are classified by percentage of N.meningitidis serogroup B invasive strains killed using enc-hSBA and the corresponding 2- sided 95% CI based on Clopper-Pearson method is calculated for each vaccine group. Analysis was performed on the FAS.

End point type	Secondary

End point timeframe:

At 1 month after the vaccination schedule (Day 91 for MenB_0_2_6 group [2 dose schedule])

Notes:

[45] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: As specified in the Protocol, the analysis assesses the percentage of serogroup B invasive disease strains killed within a subject using enc-hSBA of the rMenB+OMV vaccine.

End point values	MenB_0_2_6 Group			
Subject group type	Reporting group			
Number of subjects analysed	831			
Units: Percentage of participants				
number (confidence interval 95%)				
>=50% killed strains	98.6 (97.5 to 99.3)			
>=55% killed strains	97.7 (96.5 to 98.6)			
>=60% killed strains	96.5 (95 to 97.7)			

>=65% killed strains	92.2 (90.1 to 93.9)			
>=70% killed strains	84.8 (82.2 to 87.2)			
>=75% killed strains	75.7 (72.6 to 78.6)			
>=80% killed strains	66.7 (63.3 to 69.9)			
>=85% killed strains	49.7 (46.2 to 53.2)			
>=90% killed strains	33.8 (30.6 to 37.1)			
>=95% killed strains	16.2 (13.8 to 18.9)			
100% killed strains	7.7 (6 to 9.7)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with hSBA titers >= LLOQ for each and all serogroup B indicator strains at Day 1 and at 1 month after vaccination with rMenB+OMV NZ (0,2,6-months and 0,6-months) and last dose of MenABCWY (ABCWY group-pooled lots)

End point title	Percentage of participants with hSBA titers >= LLOQ for each and all serogroup B indicator strains at Day 1 and at 1 month after vaccination with rMenB+OMV NZ (0,2,6-months and 0,6-months) and last dose of MenABCWY (ABCWY group-pooled lots)[46]

End point description:

The immune response to rMenB+OMV NZ and MenABCWY vaccine is evaluated by measuring bactericidal activity against each (individual response) and all (composite response) N. meningitidis serogroup B indicator strains(M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively). As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. Analysis was performed on the FAS.

End point type	Secondary

End point timeframe:

At Day 1 (pre-vaccination) and1 month after the vaccination schedule (i.e., Day 211 for MenB_0_2_6 group [3 dose schedule], MenB_0_6 group and ABCWY_Pooled group)

Notes:

[46] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: As specified in the Protocol, the analysis assesses the immune response of the rMenB+OMV and MenABCWY vaccines against N. meningitidis serogroup B indicator strains.

End point values	MenB_0_2_6 Group	MenB_0_6 Group	ABCWY_Pooled	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	749	731	780	
Units: Percentage of participants				
number (confidence interval 95%)				
fHbp (M14459) Ab, Day 1 (N=749,730,762)	4.9 (3.5 to 6.7)	3.4 (2.2 to 5)	5.4 (3.9 to 7.2)	

fHbp (M14459) Ab, Day 211 (N=690,707,738)	97.4 (95.9 to 98.4)	94.6 (92.7 to 96.2)	95.9 (94.2 to 97.2)	
NadA (96217) Ab, Day 1 (N=744,731,780)	6.2 (4.6 to 8.2)	4.4 (3.0 to 6.1)	6.2 (4.6 to 8.1)	
NadA (96217) Ab, Day 211 (N=691,707,734)	100 (99.5 to 100)	98 (96.7 to 98.9)	96.2 (94.5 to 97.5)	
NHBA (M13520) Ab, Day 1 (N=749,731,764)	23.2 (20.3 to 26.4)	20.9 (18 to 24.1)	18.5 (15.8 to 21.4)	
NHBA (M13520) Ab, Day 211 (N=695,711,738)	97.0 (95.4 to 98.1)	97.5 (96.0 to 98.5)	95.3 (93.5 to 96.7)	
PorA (NZ98/254) Ab, Day 1 (N=738,716,751)	2.3 (1.3 to 3.7)	1.4 (0.7 to 2.6)	2.1 (1.2 to 3.4)	
PorA (NZ98/254) Ab, Day 211 (N=657,684,709)	85.8 (82.9 to 88.4)	82.6 (79.5 to 85.4)	75.3 (72.0 to 78.5)	
Composite Response, Day=1 (N=727,708,747)	1.1 (0.5 to 2.2)	0.6 (0.2 to 1.4)	1.1 (0.5 to 2.1)	
Composite Response, Day=211 (N=654,683,707)	83.3 (80.3 to 86.1)	80.7 (77.5 to 83.6)	71.4 (67.9 to 74.7)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with hSBA titers >= LLOQ for each and all serogroup B indicator strains at Day 1 and at 1 month after vaccination with rMenB+OMV NZ (0,2-months)

End point title	Percentage of participants with hSBA titers >= LLOQ for each and all serogroup B indicator strains at Day 1 and at 1 month after vaccination with rMenB+OMV NZ (0,2-months)[47]

End point description:

The immune response to rMenB+OMV NZ is evaluated by measuring bactericidal activity against each (individual response) and all (composite response) N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively). Analysis was performed on the FAS.

End point type	Secondary

End point timeframe:

At Day 1 (pre-vaccination) and1 month after the vaccination schedule (i.e., Day 91 for MenB_0_2_6 group [2 dose schedule])

Notes:

[47] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: As specified in the Protocol, the analysis assesses the immune response of the rMenB+OMV vaccine against N. meningitidis serogroup B indicator strain.

End point values	MenB_0_2_6 Group			
Subject group type	Reporting group			
Number of subjects analysed	753			
Units: Percentage of participants				
number (confidence interval 95%)				
fHbp (M14459) Ab, Day 1 (N=749)	4.9 (3.5 to 6.7)			
fHbp (M14459) Ab, Day 91 (N=750)	92.9 (90.9 to 94.7)			
NadA (96217) Ab, Day 1 (N=744)	6.2 (4.6 to 8.2)			

NadA (96217) Ab, Day 91 (N=753)	99.5 (98.6 to 99.9)			
NHBA (M13520) Ab, Day 1 (N=749)	23.2 (20.3 to 26.4)			
NHBA (M13520) Ab, Day 91 (N=750)	96.1 (94.5 to 97.4)			
PorA N (NZ98/254) Ab, Day 1 (N=738)	2.3 (1.3 to 3.7)			
PorA N (NZ98/254) Ab, Day 91 (N=745)	80 (76.9 to 82.8)			
Composite Response, Day=1 (N=727)	1.1 (0.5 to 2.2)			
Composite Response, Day=91 (N=744)	75.5 (72.3 to 78.6)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with 4-fold rise in hSBA titers for each of the serogroup B strains at 1 month after vaccination with rMenB+OMV NZ (0,2,6-months and 0,6-months) and last dose of MenABCWY (ABCWY group-pooled lots)

End point title	Percentage of participants with 4-fold rise in hSBA titers for each of the serogroup B strains at 1 month after vaccination with rMenB+OMV NZ (0,2,6-months and 0,6-months) and last dose of MenABCWY (ABCWY group-pooled lots)[48]

End point description:

The immune response to 3 dose (0,2,6-M), 2 dose (0,6-M) schedule of rMenB+OMV NZ and 2 doses of MenABCWY vaccine was evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B test strains- M14459, 96217, NZ98/254 and M13520 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively compared to baseline. Four-fold rise per each indicator strain was defined as a post-vaccination hSBA titre ≥16 for subjects with a pre-vaccination hSBA titre <4 a post-vaccination hSBA titer ≥4 times the LLOQ for subjects with a pre-vaccination hSBA titre ≥LOD and <LLOQ a post-vaccination hSBA titre ≥4 times the pre-vaccination hSBA titre for participants with a pre-vaccination hSBA titre ≥ LLOQ. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. Analysis was performed on the FAS.

End point type	Secondary

End point timeframe:

At 1 month after the vaccination schedule (i.e., Day 211 for MenB_0_2_6 group [3 dose schedule], MenB_0_6 group and ABCWY_Pooled group) compared to Day 1 (baseline)

Notes:

[48] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: As specified in the Protocol, the analysis assesses the immune response of the rMenB+OMV and MenABCWY vaccines against N. meningitidis serogroup B indicator strains.

End point values	MenB_0_2_6 Group	MenB_0_6 Group	ABCWY_Pooled	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	685	704	731[49]	
Units: Percentage of participants				
number (confidence interval 95%)				
fHbp (M14459) Ab (N=679,699, 729)	86.7 (84.0 to 89.2)	82.4 (79.4 to 85.2)	78.9 (75.7 to 81.8)	
NadA (96217) Ab (N=679,700,725)	98.7 (97.5 to 99.4)	95.3 (93.4 to 96.7)	92.3 (90.1 to 94.1)	

NHBA (M13520) Ab (N=685,704,731)	66.9 (63.2 to 70.4)	69.5 (65.9 to 72.8)	61.1 (57.5 to 64.7)	
PorA (NZ98/254) Ab (N=637,664,693)	56.5 (52.6 to 60.4)	57.2 (53.4 to 61.0)	42.4 (38.7 to 46.2)	

Notes:

[49] - Analysis of final results for the ABCWY group is ongoing and will be updated subsequently.

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with 4-fold rise in hSBA titers for each of the serogroup B strains at 1 month after vaccination with rMenB+OMV NZ (0,2 months)

End point title	Percentage of participants with 4-fold rise in hSBA titers for each of the serogroup B strains at 1 month after vaccination with rMenB+OMV NZ (0,2 months)[50]

End point description:

The immune response to 2 dose (0,2-M) is evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B test strains- M14459, 96217, NZ98/254 and M13520 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively compared to baseline. Four-fold rise per each indicator strain was defined as a post-vaccination hSBA titre ≥16 for participants with a pre-vaccination hSBA titre <4 a post-vaccination hSBA titre ≥4 times the LLOQ for subjects with a pre-vaccination hSBA titre ≥LOD and <LLOQ a post-vaccination hSBA titre ≥4 times the pre-vaccination hSBA titre for subjects with a pre-vaccination hSBA titre ≥ LLOQ. Analysis was performed on the FAS.

End point type	Secondary

End point timeframe:

At 1 month after the vaccination schedule (i.e., Day 91 for MenB_0_2_6 [2-dose schedule]) compared to Day 1 (baseline)

Notes:

[50] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: As specified in the Protocol, the analysis assesses the immune response of the rMenB+OMV vaccines against N. meningitidis serogroup B indicator strains.

End point values	MenB_0_2_6 Group			
Subject group type	Reporting group			
Number of subjects analysed	739			
Units: Percentage of participants				
number (confidence interval 95%)				
fHbp (M14459) Ab (N=739)	74.6 (71.3 to 77.7)			
NadA (96217) Ab (N=738)	96.3 (94.7 to 97.6)			
NHBA (M13520) Ab (N=739)	58.5 (54.8 to 62.0)			
PorA (NZ98/254) Ab (N=724)	53.5 (49.7 to 57.1)			

Statistical analyses

No statistical analyses for this end point

Secondary: hSBA Geometric Mean Titres (GMTs) against each of the N. meningitidis

serogroup B strains at Day 1 and at 1 month after vaccination with rMenB+OMV NZ (0,2,6-months, 0,6-months) and last dose of MenABCWY (ABCWY group-pooled lots)

End point title	hSBA Geometric Mean Titres (GMTs) against each of the N. meningitidis serogroup B strains at Day 1 and at 1 month after vaccination with rMenB+OMV NZ (0,2,6-months, 0,6-months) and last dose of MenABCWY (ABCWY group-pooled lots)[51]

End point description:

The immune response to rMenB+OMV NZ and MenABCWY vaccine was evaluated by measuring bactericidal activity against N. meningitidis serogroup B test strains in terms of GMTs after vaccination compared to baseline (Day 1). For each N. meningitidis serogroup B test strain (M14459, M13520, 96217 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively), The GMTs (After vaccination/baseline) are calculated, with their associated 2-sided 95% CIs. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. Analysis was performed on the FAS.

End point type	Secondary

End point timeframe:

At Day 1 (pre-vaccination) and at 1 month after the vaccination schedule (i.e., Day 211 for MenB_0_2_6 group (3 dose schedule), MenB_0_6 group and ABCWY_Pooled group)

Notes:

[51] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: As specified in the Protocol, the analysis assesses the immune response of the rMenB+OMV and MenABCWY vaccines against N. meningitidis serogroup B indicator strains.

End point values	MenB_0_2_6 Group	MenB_0_6 Group	ABCWY_Pooled	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	749	731	780	
Units: Titers				
geometric mean (confidence interval 95%)				
fHbp (M14459) Ab, Day 1 (N=749,730,762)	2.8 (2.7 to 2.8)	2.7 (2.6 to 2.8)	2.8 (2.7 to 2.9)	
fHbp (M14459) Ab, Day 211 (N=690,707,738)	30.8 (28.3 to 33.5)	28.1 (25.9 to 30.6)	25 (23 to 27.1)	
NadA (96217) Ab, Day 1 (N=744,731,780)	8.4 (8.1 to 8.6)	8.3 (8 to 8.6)	8.5 (8.2 to 8.8)	
NadA (96217) Ab, Day 211 (N=691,707,734)	267.2 (243.7 to 293)	215.1 (196.2 to 235.9)	150.6 (137.3 to 165.2)	
NHBA (M13520) Ab, Day 1 (N=749,731,764)	3.4 (3.1 to 3.7)	3.2 (3 to 3.5)	3.1 (2.8 to 3.4)	
NHBA (M13520) Ab, Day 211 (N=695,711,738)	30.6 (27.7 to 33.7)	33.2 (30.2 to 36.6)	25.2 (22.9 to 27.8)	
PorA (NZ98/254) Ab, Day 1 (N=738,716,751)	3.2 (3.1 to 3.2)	3.1 (3 to 3.2)	3.1 (3.1 to 3.2)	
PorA (NZ98/254) Ab, Day 211 (N=657,684,709)	18.1 (16.3 to 20.1)	17.7 (15.9 to 19.6)	12.9 (11.6 to 14.4)	

Statistical analyses

No statistical analyses for this end point

Secondary: hSBA GMTs against each of the N. meningitidis serogroup B strains at Day 1 and at 1 month after vaccination with rMenB+OMV NZ (0,2-months)

End point title	hSBA GMTs against each of the N. meningitidis serogroup B strains at Day 1 and at 1 month after vaccination with rMenB+OMV NZ (0,2-months)[52]

End point description:

The immune response to rMenB+OMV NZ and MenABCWY vaccine was evaluated by measuring bactericidal activity against N. meningitidis serogroup B test strains in terms of GMTs after vaccination compared to baseline (Day 1). For each N. meningitidis serogroup B test strain (M14459, M13520, 96217 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively), The GMTs (After vaccination/baseline) were calculated, with their associated 2-sided 95% CIs. Analysis was performed on the FAS.

End point type	Secondary

End point timeframe:

At Day 1 (pre-vaccination) and at 1 month after the vaccination schedule (i.e., Day 91 for MenB_0_2_6 group [2-dose schedule])

Notes:

[52] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: As specified in the Protocol, the analysis assesses the immune response of the rMenB+OMV vaccine against N. meningitidis serogroup B indicator strains.

End point values	MenB_0_2_6 Group			
Subject group type	Reporting group			
Number of subjects analysed	753			
Units: Titers				
geometric mean (confidence interval 95%)				
fHbp (M14459) Ab, Day 1(N=749)	2.8 (2.7 to 2.8)			
fHbp (M14459) Ab, Day 91(N=750)	20.9 (18.9 to 23.1)			
NadA (96217) Ab, Day 1(N=744)	8.4 (8.1 to 8.6)			
NadA (96217) Ab, Day 91(N=753)	178.5 (161.7 to 197.2)			
NHBA (M13520) Ab, Day 1(N=749)	3.4 (3.1 to 3.7)			
NHBA (M13520) Ab, Day 91(N=750)	27.2 (24.1 to 30.6)			
PorA (NZ98/254) Ab, Day 1(N=738)	3.2 (3.1 to 3.2)			
PorA (NZ98/254) Ab, Day 91(N=745)	17.1 (15.2 to 19.3)			

Statistical analyses

No statistical analyses for this end point

Secondary: hSBA Geometric Mean Ratios (GMRs) for each of the N. meningitidis serogroup B strains at 1 month after vaccination with rMenB+OMV NZ (0,2,6-months, 0,6-months) and last dose of MenABCWY (ABCWY group-pooled lots)

End point title	hSBA Geometric Mean Ratios (GMRs) for each of the N. meningitidis serogroup B strains at 1 month after vaccination with rMenB+OMV NZ (0,2,6-months, 0,6-months) and last dose of MenABCWY (ABCWY group-pooled lots)[53]

End point description:

The immune response to rMenB+OMV NZ vaccine was evaluated by measuring bactericidal activity against N. meningitidis serogroup B test strains after vaccination compared to baseline (Day 1). For each N. meningitidis serogroup B test strain (M14459, M13520, 96217 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively), the GMRs (after vaccination/baseline) are calculated, with

their associated 2-sided 95% CIs. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. Analysis was performed on the FAS.

End point type	Secondary

End point timeframe:

At 1 month after the vaccination schedule (i.e., Day 211 for MenB_0_2_6 group (3 dose schedule), MenB_0_6 group and ABCWY_Pooled group) compared to Day 1 (baseline)

Notes:

[53] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: As specified in the Protocol, the analysis assesses the immune response of the rMenB+OMV and MenABCWY vaccines against N. meningitidis serogroup B indicator strains.

End point values	MenB_0_2_6 Group	MenB_0_6 Group	ABCWY_Pooled	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	685	704	731	
Units: Ratio				
geometric mean (confidence interval 95%)				
fHbp (M14459) Ab (N=679,699,729)	11.2 (10.3 to 12.2)	10.5 (9.6 to 11.4)	9 (8.2 to 9.8)	
NadA (96217) Ab (N=679,700,725)	32.1 (29.1 to 35.3)	25.8 (23.5 to 28.4)	17.7 (16 to 19.4)	
NHBA (M13520) Ab (N=685,704,731)	9.1 (8.2 to 10.1)	10.6 (9.5 to 11.7)	8.2 (7.4 to 9.1)	
PorA (NZ98/254) Ab (N=637,664,693)	5.8 (5.2 to 6.5)	5.8 (5.2 to 6.4)	4.1 (3.7 to 4.6)	

Statistical analyses

No statistical analyses for this end point

Secondary: hSBA GMRs for each of the N. meningitidis serogroup B strains at 1 month after vaccination with rMenB+OMV NZ (0,2-months)

End point title	hSBA GMRs for each of the N. meningitidis serogroup B strains at 1 month after vaccination with rMenB+OMV NZ (0,2-months)[54]

End point description:

The immune response to rMenB+OMV NZ vaccine was evaluated by measuring bactericidal activity against N. meningitidis serogroup B test strains after vaccination compared to baseline (Day 1). For each N. meningitidis serogroup B test strain (M14459, M13520, 96217 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively), the GMRs (after vaccination/baseline) are calculated, with their associated 2-sided 95% CIs. Analysis was performed on the FAS.

End point type	Secondary

End point timeframe:

At 1 month after the vaccination schedule (i.e., Day 91 for MenB_0_2_6 group [2-dose schedule]) compared to Day 1 (baseline)

Notes:

[54] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: As specified in the Protocol, the analysis assesses the immune response of the rMenB+OMV vaccines against N. meningitidis serogroup B indicator strains.

End point values	MenB_0_2_6 Group			
Subject group type	Reporting group			
Number of subjects analysed	739			
Units: Ratio				
geometric mean (confidence interval 95%)				
fHbp (M14459) Ab (N=739)	7.7 (6.9 to 8.5)			
NadA (96217) Ab (N=738)	21.7 (19.5 to 24)			
NHBA (M13520) Ab (N=739)	8 (7.1 to 9)			
PorA (NZ98/254) Ab (N=724)	5.5 (4.9 to 6.2)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with hSBA titers >= LLOQ for each of the N. meningitidis serogroups A,C,W,Y at Day 1 and at 1 month after the first and the last MenABCWY vaccination for ABCWY_Pooled group and 1 month after the MenACWY vaccine for ACWY group

End point title	Percentage of participants with hSBA titers >= LLOQ for each of the N. meningitidis serogroups A,C,W,Y at Day 1 and at 1 month after the first and the last MenABCWY vaccination for ABCWY_Pooled group and 1 month after the MenACWY vaccine for ACWY group[55]

End point description:

The immune responses to MenABCWY and MenACWY vaccines were evaluated by measuring bactericidal activity against N. meningitidis serogroups A, C, W and Y after vaccination compared to baseline (Day 1) and expressed as the percentage of participants with hSBA titers >= LLOQ for serogroups A, C, W and Y at baseline and 1 month after vaccination schedule of MenABCWY and MenACWY vaccines. As pre-specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. Analysis was performed on the FAS.

End point type	Secondary

End point timeframe:

At Day 1, and 1 month after vaccination schedule (i.e, at Day 31 for ABCWY group [pooled lots -first dose] and for ACWY Group, and at Day 211 for ABCWY group [pooled lots – second dose])

Notes:

[55] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the immune response of the MenABCWY and MenACWY vaccines against N. meningitidis serogroups A, C, W, and Y.

End point values	ABCWY_Pooled	ACWY Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1489	141		
Units: Percentage of participants				
number (confidence interval 95%)				
Men A, Day 1 (N=1452, 137)	9.2 (7.7 to 10.8)	11.7 (6.8 to 18.3)		
Men A, Day 31 (N=132, 133)	79.5 (71.7 to 86.1)	90.2 (83.9 to 94.7)		
Men A, Day 211 (N=1446)	98.6 (97.9 to 99.2)	99999 (99999 to 99999)		

Men C, Day 1 (N=1487, 139)	29.8 (27.5 to 32.2)	28.8 (21.4 to 37.1)		
Men C, Day 31 (N=139,136)	74.8 (66.8 to 81.8)	64.0 (55.3 to 72.0)		
Men C, Day 211 (N=1457)	99.6 (99.1 to 99.8)	99999 (99999 to 99999)		
Men W, Day 1 (N=1473,140)	12.6 (10.9 to 14.4)	12.9 (7.8 to 19.6)		
Men W, Day 31 (N=142,137)	80.3 (72.8 to 86.5)	69.3 (60.9 to 76.9)		
Men W, Day 211 (N=1463)	99.2 (98.7 to 99.6)	99999 (99999 to 99999)		
Men Y, Day 1 (N=1489,141)	12.2 (10.6 to 14.0)	13.5 (8.3 to 20.2)		
Men Y, Day 91 (N=146,140)	82.2 (75.0 to 88.0)	80.0 (72.4 to 86.3)		
Men Y, Day 211 (N=1461)	99.2 (98.7 to 99.6)	99999 (99999 to 99999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants with 4-fold rise in hSBA titers for each of the N. meningitidis serogroups A, C, W and Y at 1 month after the first MenABCWY dose for ABCWY_Pooled group compared to the MenACWY vaccine for ACWY group relative to baseline (Day 1)

End point title	Percentage of participants with 4-fold rise in hSBA titers for each of the N. meningitidis serogroups A, C, W and Y at 1 month after the first MenABCWY dose for ABCWY_Pooled group compared to the MenACWY vaccine for ACWY group relative to baseline (Day 1)[56]

End point description:

The immune response to MenABCWY vaccine compared to MenACWY vaccine was evaluated by measuring bactericidal activity against each of the N. meningitidis serogroups A, C, W and Y at Day 31 compared to baseline (Day 1). Four-fold rise is defined as: - If the pre-vaccination hSBA titer is < 4, then post-vaccination hSBA titer should be ≥ 16. - If the pre-vaccination hSBA titer is ≥ LOD but < LLOQ, then post-vaccination hSBA titer should be ≥ 4 times the LLOQ. - If the pre-vaccination hSBA titer is ≥ LLOQ, then post-vaccination hSBA titer should be ≥ 4 times the pre-vaccination hSBA titer. The corresponding 2- sided 95% CI based on Clopper-Pearson method is calculated for each vaccine group. As pre-specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. Analysis was performed on the FAS.

End point type	Secondary

End point timeframe:

At 1 month after vaccination schedule (i.e, at Day 31 for ABCWY group [pooled group] and for ACWY Group) relative to baseline (Day 1)

Notes:

[56] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the effectiveness of the rMenB+OMV vaccine compared to one dose of MenACWY vaccination in the ACWY group.

End point values	ABCWY_Pooled	ACWY Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	146	140		
Units: Percentage of participants				
number (confidence interval 95%)				
Men A (N=127,129)	74.0 (65.5 to 81.4)	86.0 (78.8 to 91.5)		
Men C (N=139,134)	66.9 (58.4 to 74.6)	56.7 (47.9 to 65.2)		
Men W (N=139,136)	74.1 (66.0 to 81.2)	66.2 (57.6 to 74.1)		
Men Y (N=146,140)	76.0 (68.3 to 82.7)	72.1 (63.9 to 79.4)		

Statistical analyses

No statistical analyses for this end point

Secondary: hSBA GMTs against each of the N. meningitidis serogroups A, C, W and Y at Day 1 and 1 month after the first and the last MenABCWY vaccination for the ABCWY_Pooled group and at 1 month after the MenACWY vaccination for ACWY Group

End point title	hSBA GMTs against each of the N. meningitidis serogroups A, C, W and Y at Day 1 and 1 month after the first and the last MenABCWY vaccination for the ABCWY_Pooled group and at 1 month after the MenACWY vaccination for ACWY Group[57]

End point description:

The immune responses to MenABCWY and MenACWY vaccines are evaluated by measuring bactericidal activity against N. meningitidis serogroups A, C, W and Y in terms of GMTs after vaccination compared to baseline (Day 1). For each N. meningitidis serogroups A, C, W and Y, the GMTs (after vaccination/baseline) are calculated, with their associated 2-sided 95% CIs. As pre-specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. Analysis was performed on the FAS.

End point type	Secondary

End point timeframe:

At Day 1, and 1 month after vaccination schedule (i.e, at Day 31 for ABCWY group [pooled lots -first dose] and for ACWY Group, and at Day 211 for ABCWY group [pooled lots – second dose])

Notes:

[57] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: As specified in the Protocol, the analysis assesses the immune response of the MenABCWY and MenACWY vaccines against N. meningitidis serogroups A, C, W, and Y.

End point values	ABCWY_Pooled	ACWY Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1489	141		
Units: Titers				
geometric mean (confidence interval 95%)				
Men A, Day 1 (N=1452,137)	11.1 (10.3 to 11.9)	12.7 (10.9 to 14.8)		
Men A, Day 31 (N=132,133)	175.3 (121.2 to 253.3)	474.8 (331.3 to 680.3)		

Men A, Day 211 (N=1446)	352.0 (322.0 to 384.7)	99999 (99999 to 99999)		
Men C, Day 1 (N=1487,139)	12.0 (10.9 to 13.3)	11.4 (9.1 to 14.3)		
Men C, Day 31 (N=139,136)	674.8 (355.9 to 1279.4)	379.0 (204.4 to 703.0)		
Men C, Day 211 (N=1457)	1162.5 (1015.7 to 1330.5)	99999 (99999 to 99999)		
Men W, Day 1 (N=1473,140)	8.0 (7.4 to 8.7)	7.4 (6.2 to 8.9)		
Men W, Day 31 (N=142,137)	374.0 (243.4 to 574.8)	194.3 (128.3 to 294.2)		
Men W, Day 211 (N=1463)	666.5 (603.2 to 736.3)	99999 (99999 to 99999)		
Men Y, Day 1 (N=1489,141)	9.3 (8.7 to 10.0)	9.9 (8.6 to 11.5)		
Men Y, Day 31 (N=146,140)	375.4 (246.9 to 570.7)	320.9 (213.8 to 481.7)		
Men Y, Day 211 (N=1461)	655.9 (587.0 to 733.0)	99999 (99999 to 99999)		

Statistical analyses

No statistical analyses for this end point

Secondary: GMRs for each of the N. meningitidis serogroups A, C, W and Y at 1 month after the first and the last MenABCWY vaccination for the ABCWY _Pooled group and at 1 month after the MenACWY vaccination for ACWY Group

End point title	GMRs for each of the N. meningitidis serogroups A, C, W and Y at 1 month after the first and the last MenABCWY vaccination for the ABCWY _Pooled group and at 1 month after the MenACWY vaccination for ACWY Group[58]

End point description:

The immune responses to MenABCWY and MenACWY vaccines are evaluated by measuring bactericidal activity against N. meningitidis serogroups A, C, W and Y. For each N. meningitidis serogroups A, C, W and Y, the GMRs (after vaccination/baseline) are calculated, with their associated 2-sided 95% CIs. As pre-specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. Analysis was performed on the FAS.

End point type	Secondary

End point timeframe:

1 month after vaccination schedule (i.e, at Day 31 for ABCWY group [pooled lots -first dose] and for ACWY Group, and at Day 211 for ABCWY group [pooled lots – second dose]) compared to baseline (Day 1)

Notes:

[58] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the immune response of the MenABCWY and MenACWY against N. meningitidis serogroups A, C, W, and Y.

End point values	ABCWY_Pooled	ACWY Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1446	140		
Units: Ratio				
geometric mean (confidence interval 95%)				
Men A, Day 31 (N=127,129)	11.8 (7.9 to 17.7)	31.8 (21.4 to 47.1)		
Men A, Day 211 (N=1397)	31.2 (28.3 to 34.5)	99999 (99999 to 99999)		
Men C, Day 31 (N=139,134)	30.9 (16.9 to 56.2)	22.9 (12.8 to 41.1)		
Men C, Day 211 (N=1439)	96.9 (84.5 to 111.1)	99999 (99999 to 99999)		
Men W, Day 31 (N=139,136)	32.9 (21.7 to 50.0)	23.2 (15.5 to 34.7)		
Men W, Day 211 (N=1432)	83.8 (74.9 to 93.8)	99999 (99999 to 99999)		
Men Y, Day 31 (N=146,140)	28.1 (18.3 to 43.2)	25.6 (16.9 to 38.8)		
Men Y, Day 211 (N=1446)	70.2 (62.3 to 79.1)	99999 (99999 to 99999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Total Immunoglobulin G (IgG) antibodies concentrations against N. meningitidis serogroups A, C, W and Y at Day 1 and 1 month after the first and the last MenABCWY vaccination for ABCWY _Pooled group and 1 month after the MenACWY vaccination for ACWY Group

End point title	Total Immunoglobulin G (IgG) antibodies concentrations against N. meningitidis serogroups A, C, W and Y at Day 1 and 1 month after the first and the last MenABCWY vaccination for ABCWY _Pooled group and 1 month after the MenACWY vaccination for ACWY Group[59]

End point description:

The immune responses to MenABCWY and MenACWY vaccines were evaluated by measuring the total IgG in terms of electrochemiluminescence-based multiplex (EGL) geometric mean concentrations (GMCs) which was an alternative assay to Enzyme-Linked Immunosorbent Assay (ELISA). EGL (validated assay) was used because ELISA is not validated. As pre- specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group. Analysis was performed on the FAS.

End point type	Secondary

End point timeframe:

At Day 1, and 1 month after vaccination schedule (i.e, at Day 31 for ABCWY group [pooled lots -first dose] and for ACWY Group, and at Day 211 for ABCWY group [pooled lots - second dose])

Notes:

[59] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As specified in the Protocol, the analysis assesses the immune response of the MenABCWY and MenACWY vaccines against N. meningitidis serogroups A, C, W, and Y.

End point values	ABCWY_Pooled	ACWY Group		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	179	172		
Units: microgram per milliliter(µg/mL)				
geometric mean (confidence interval 95%)				
Men A, Day 1 (N=170, 179)	1.9 (1.6 to 2.2)	2.3 (2.0 to 2.7)		
Men A, Day 31 (N=168, 177)	18.1 (13.8 to 23.8)	53.7 (40.8 to 70.7)		
Men A, Day 211 (N=164)	30.2 (23.3 to 39.2)	99999 (99999 to 99999)		
Men C, Day 1 (N=170, 179)	0.7 (0.6 to 0.8)	0.8 (0.7 to 1.0)		
Men C, Day 31 (N=170, 175)	15.5 (11.6 to 20.7)	13.8 (10.4 to 18.4)		
Men C, Day 211 (N=163)	17.0 (13.1 to 22.0)	99999 (99999 to 99999)		
Men W, Day 1 (N=170, 179)	0.5 (0.4 to 0.6)	0.6 (0.5 to 0.7)		
Men W, Day 31 (N=172, 178)	9.1 (6.5 to 12.8)	8.4 (6.0 to 11.6)		
Men W, Day 211 (N=164)	21.7 (16.0 to 29.5)	99999 (99999 to 99999)		
Men Y, Day 1 (N=170, 179)	0.9 (0.7 to 1.0)	0.9 (0.8 to 1.0)		
Men Y, Day 31 (N=172, 178)	12.9 (9.2 to 18.0)	14.3 (10.2 to 19.8)		
Men Y, Day 211 (N=164)	26.3 (19.6 to 35.4)	99999 (99999 to 99999)		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

SAEs and Non-serious AEs (Other AEs) were collected through the entire period of the study (from Day 1 up to study end [Day 361])

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	25.0

Reporting groups

Reporting group title	MenB_0_2_6 Group

Reporting group description:

Participants received 3 doses of rMenB+OMV NZ vaccine on Day 1, Day 61 and Day 181. Participants received 1 dose of MenACWY vaccine at Day 211 as a standard of care.

Reporting group title	ABCWY_Pooled

Reporting group description:

Participants received 2 doses of either MenABCWY Lot 1, Lot 2, or Lot 3 vaccine on Day 1 and Day 181 and 1 dose of placebo on Day 61. Participants received 1 dose of placebo on Day 211 to maintain blinding. To evaluate the effectiveness of 2 doses of the MenABCWY vaccines against rMenB+OMV and MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.

Reporting group title	ACWY Group

Reporting group description:

Participants received 1 dose of MenACWY vaccine at Day 1,1 dose of placebo at Day 61 and 1 dose of rMenB+OMV NZ vaccine on Day 181. Participants received 1 dose of rMenB+OMV NZ vaccine on Day 211 as standard of care.

Reporting group title	MenB_0_6 Group

Reporting group description:

Participants received 2 doses of rMenB+OMV NZ vaccine on Day 1, and Day 181, 1 dose of MenACWY vaccine on Day 61. Participants received 1 dose of Placebo on Day 211 to maintain blinding.

Serious adverse events	MenB_0_2_6 Group	ABCWY_Pooled	ACWY Group
Total subjects affected by serious adverse events			
subjects affected / exposed	20 / 897 (2.23%)	25 / 1657 (1.51%)	5 / 178 (2.81%)
number of deaths (all causes)	1	0	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Testis cancer			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain stem glioma			

subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian fibroma			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Complication of pregnancy			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Placental insufficiency			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pre-eclampsia			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			

subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Ovarian cyst ruptured			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicide attempt			

subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Substance-induced psychotic disorder			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Major depression			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression suicidal			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental disorder			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anorexia nervosa			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal ideation			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychotic disorder			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thinking abnormal			

subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Troponin T increased			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Alcohol poisoning			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Concussion			
subjects affected / exposed	3 / 897 (0.33%)	1 / 1657 (0.06%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendon rupture			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haemorrhage			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin laceration			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road traffic accident			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Post procedural haemorrhage			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Poisoning			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Overdose			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower limb fracture			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intentional overdose			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxicity to various agents			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulna fracture			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Traumatic liver injury			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury			

subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back injury			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neck injury			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head injury			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hand fracture			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain contusion			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skull fracture			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Urachal abnormality			

subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Dysarthria			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aphasia			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorder			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paresis			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Petit mal epilepsy			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Speech disorder			

subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	1 / 178 (0.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuromyelitis optica spectrum disorder			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Lymphadenitis			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Hypermetropia			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis ulcerative			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Nausea			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis toxic			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Excessive granulation tissue			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vancomycin infusion reaction			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urethral stenosis			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Intervertebral disc protrusion			

subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhabdomyolysis			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	1 / 897 (0.11%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonsillar abscess			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tooth abscess			

subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post-acute COVID-19 syndrome			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngeal abscess			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infected dermal cyst			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Type 1 diabetes mellitus			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	MenB_0_6 Group		
Total subjects affected by serious adverse events			
subjects affected / exposed	22 / 906 (2.43%)		
number of deaths (all causes)	1		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Testis cancer			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Brain stem glioma			

subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ovarian fibroma				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Vascular disorders				
Haematoma				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pregnancy, puerperium and perinatal conditions				
Abortion spontaneous				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Complication of pregnancy				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Placental insufficiency				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pre-eclampsia				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
General disorders and administration site conditions				
Pyrexia				

subjects affected / exposed	2 / 906 (0.22%)			
occurrences causally related to treatment / all	1 / 2			
deaths causally related to treatment / all	0 / 0			
Chest pain				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Immune system disorders				
Anaphylactic reaction				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Reproductive system and breast disorders				
Ovarian cyst ruptured				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory, thoracic and mediastinal disorders				
Dyspnoea				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Psychiatric disorders				
Anxiety				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Depression				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Suicide attempt				

subjects affected / exposed	2 / 906 (0.22%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Substance-induced psychotic disorder				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Major depression				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Depression suicidal				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mental disorder				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Anorexia nervosa				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Suicidal ideation				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Psychotic disorder				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Thinking abnormal				

subjects affected / exposed	0 / 906 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
Troponin T increased			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Alcohol poisoning			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Concussion			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tendon rupture			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Subdural haemorrhage			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin laceration			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Road traffic accident			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Post procedural haemorrhage			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Poisoning			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Overdose			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Lower limb fracture			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intentional overdose			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Toxicity to various agents			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ulna fracture			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Traumatic liver injury			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Injury			

subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Back injury				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Neck injury				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Head injury				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hand fracture				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Brain contusion				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Skull fracture				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tibia fracture				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Congenital, familial and genetic disorders				
Urachal abnormality				

subjects affected / exposed	0 / 906 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Dysarthria			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dizziness			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Aphasia			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Headache			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorder			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Paresis			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Petit mal epilepsy			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Speech disorder			

subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Subarachnoid haemorrhage				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Neuromyelitis optica spectrum disorder				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Blood and lymphatic system disorders				
Lymphadenitis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Eye disorders				
Hypermetropia				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal disorders				
Colitis ulcerative				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Abdominal pain				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Vomiting				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			

Nausea			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatitis toxic			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Excessive granulation tissue			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vancomycin infusion reaction			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urethral stenosis			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Intervertebral disc protrusion			

subjects affected / exposed	1 / 906 (0.11%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Rhabdomyolysis				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Infections and infestations				
Appendicitis				
subjects affected / exposed	3 / 906 (0.33%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Cellulitis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Peritonsillar abscess				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Sepsis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tonsillitis				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Tooth abscess				

subjects affected / exposed	0 / 906 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Post-acute COVID-19 syndrome			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pharyngeal abscess			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infected dermal cyst			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Type 1 diabetes mellitus			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	MenB_0_2_6 Group	ABCWY_Pooled	ACWY Group
Total subjects affected by non-serious adverse events			
subjects affected / exposed	876 / 897 (97.66%)	1599 / 1657 (96.50%)	173 / 178 (97.19%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Skin papilloma			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Benign soft tissue neoplasm			

subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Fibroadenoma of breast			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Lipoma			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Melanocytic naevus			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Vascular disorders			
Pallor			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Haematoma			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	1 / 178 (0.56%)
occurrences (all)	0	1	1
Hot flush			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Varicose vein			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Hypotension			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Hyperaemia			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Peripheral venous disease			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0

Orthostatic hypotension			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
Induration			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Administration site erythema			
subjects affected / exposed	209 / 897 (23.30%)	321 / 1657 (19.37%)	21 / 178 (11.80%)
occurrences (all)	300	397	24
Administration site induration			
subjects affected / exposed	138 / 897 (15.38%)	223 / 1657 (13.46%)	17 / 178 (9.55%)
occurrences (all)	180	273	19
Administration site pain			
subjects affected / exposed	851 / 897 (94.87%)	1561 / 1657 (94.21%)	149 / 178 (83.71%)
occurrences (all)	2229	3056	240
Administration site swelling			
subjects affected / exposed	202 / 897 (22.52%)	305 / 1657 (18.41%)	22 / 178 (12.36%)
occurrences (all)	293	401	25
Asthenia			
subjects affected / exposed	2 / 897 (0.22%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	2	1	0
Chest pain			
subjects affected / exposed	0 / 897 (0.00%)	3 / 1657 (0.18%)	1 / 178 (0.56%)
occurrences (all)	0	3	1
Chills			
subjects affected / exposed	8 / 897 (0.89%)	6 / 1657 (0.36%)	0 / 178 (0.00%)
occurrences (all)	8	6	0
Cyst			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	604 / 897 (67.34%)	1066 / 1657 (64.33%)	105 / 178 (58.99%)
occurrences (all)	1183	1807	174
Feeling hot			

subjects affected / exposed	0 / 897 (0.00%)	3 / 1657 (0.18%)	1 / 178 (0.56%)
occurrences (all)	0	3	1
Influenza like illness			
subjects affected / exposed	2 / 897 (0.22%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	2	2	0
Thirst			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Injection site haematoma			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Injection site hypoaesthesia			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Injection site induration			
subjects affected / exposed	8 / 897 (0.89%)	13 / 1657 (0.78%)	2 / 178 (1.12%)
occurrences (all)	11	14	2
Injection site mass			
subjects affected / exposed	1 / 897 (0.11%)	3 / 1657 (0.18%)	0 / 178 (0.00%)
occurrences (all)	1	3	0
Injection site pain			
subjects affected / exposed	3 / 897 (0.33%)	13 / 1657 (0.78%)	1 / 178 (0.56%)
occurrences (all)	3	13	1
Injection site pruritus			
subjects affected / exposed	2 / 897 (0.22%)	5 / 1657 (0.30%)	1 / 178 (0.56%)
occurrences (all)	4	6	1
Injection site rash			
subjects affected / exposed	1 / 897 (0.11%)	4 / 1657 (0.24%)	0 / 178 (0.00%)
occurrences (all)	1	4	0
Injection site swelling			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Injection site warmth			
subjects affected / exposed	2 / 897 (0.22%)	3 / 1657 (0.18%)	0 / 178 (0.00%)
occurrences (all)	3	3	0
Malaise			

subjects affected / exposed	4 / 897 (0.45%)	3 / 1657 (0.18%)	0 / 178 (0.00%)
occurrences (all)	5	3	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	1 / 178 (0.56%)
occurrences (all)	0	1	1
Pain			
subjects affected / exposed	4 / 897 (0.45%)	4 / 1657 (0.24%)	0 / 178 (0.00%)
occurrences (all)	5	4	0
Peripheral swelling			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	1 / 178 (0.56%)
occurrences (all)	0	1	1
Pyrexia			
subjects affected / exposed	66 / 897 (7.36%)	115 / 1657 (6.94%)	7 / 178 (3.93%)
occurrences (all)	69	122	7
Swelling			
subjects affected / exposed	1 / 897 (0.11%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	1	2	0
Injection site bruising			
subjects affected / exposed	1 / 897 (0.11%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	1	2	0
Vaccination site pain			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Vaccination site urticaria			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Vaccination site warmth			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Vessel puncture site pain			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Vaccination site pruritus			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	1 / 178 (0.56%)
occurrences (all)	0	0	1
Medical device pain			

subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Axillary pain			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Chest discomfort			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Discomfort			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Feeling cold			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Injection site discomfort			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Injection site eczema			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Injection site erythema			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Injection site haemorrhage			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Injection site papule			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Injection site paraesthesia			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Injection site reaction			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Oedema peripheral			

subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Vaccination site bruising			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Vaccination site erythema			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Vaccination site reaction			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Swelling face			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Immune system disorders			
Anaphylactoid reaction			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Drug hypersensitivity			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Food allergy			
subjects affected / exposed	2 / 897 (0.22%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	2	1	0
Hypersensitivity			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Multiple allergies			
subjects affected / exposed	2 / 897 (0.22%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	2	0	0
Seasonal allergy			
subjects affected / exposed	7 / 897 (0.78%)	9 / 1657 (0.54%)	2 / 178 (1.12%)
occurrences (all)	7	9	2
Allergy to animal			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0

Allergy to arthropod sting			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Dust allergy			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Social circumstances			
Menarche			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Reproductive system and breast disorders			
Heavy menstrual bleeding			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Breast cyst			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Breast inflammation			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Breast mass			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Breast tenderness			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Dysmenorrhoea			
subjects affected / exposed	14 / 897 (1.56%)	25 / 1657 (1.51%)	6 / 178 (3.37%)
occurrences (all)	19	31	6
Endometriosis			
subjects affected / exposed	2 / 897 (0.22%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	2	1	0
Intermenstrual bleeding			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Nipple enlargement			

subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Ovarian cyst			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Penile rash			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Premenstrual syndrome			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Testicular pain			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Vaginal haemorrhage			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Menstruation irregular			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Abnormal uterine bleeding			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Amenorrhoea			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Bartholin's cyst			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Breast discharge			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Breast haematoma			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Breast pain			

subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Menstruation delayed			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Premenstrual pain			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Uterine spasm			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Respiratory, thoracic and mediastinal disorders			
Rhinorrhoea			
subjects affected / exposed	4 / 897 (0.45%)	8 / 1657 (0.48%)	2 / 178 (1.12%)
occurrences (all)	4	8	2
Asthma			
subjects affected / exposed	4 / 897 (0.45%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	5	2	0
Cough			
subjects affected / exposed	4 / 897 (0.45%)	16 / 1657 (0.97%)	3 / 178 (1.69%)
occurrences (all)	4	16	3
Dyspnoea			
subjects affected / exposed	1 / 897 (0.11%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	1	2	0
Epistaxis			
subjects affected / exposed	1 / 897 (0.11%)	4 / 1657 (0.24%)	1 / 178 (0.56%)
occurrences (all)	1	4	1
Nasal congestion			
subjects affected / exposed	12 / 897 (1.34%)	16 / 1657 (0.97%)	0 / 178 (0.00%)
occurrences (all)	13	18	0
Oropharyngeal pain			
subjects affected / exposed	12 / 897 (1.34%)	29 / 1657 (1.75%)	0 / 178 (0.00%)
occurrences (all)	12	29	0
Respiratory tract congestion			

subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Rhinalgia			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Rhinitis allergic			
subjects affected / exposed	2 / 897 (0.22%)	3 / 1657 (0.18%)	1 / 178 (0.56%)
occurrences (all)	2	3	1
Sneezing			
subjects affected / exposed	2 / 897 (0.22%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	2	1	0
Upper-airway cough syndrome			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Wheezing			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Tonsillolith			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Bronchial hyperreactivity			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Increased upper airway secretion			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Pleuritic pain			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Respiratory disorder			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Throat clearing			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Hiccups			

subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	6 / 897 (0.67%)	11 / 1657 (0.66%)	0 / 178 (0.00%)
occurrences (all)	6	11	0
Anorexia nervosa			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Aggression			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Adjustment disorder with depressed mood			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Adjustment disorder			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Attention deficit hyperactivity disorder			
subjects affected / exposed	0 / 897 (0.00%)	4 / 1657 (0.24%)	0 / 178 (0.00%)
occurrences (all)	0	4	0
Anxiety disorder			
subjects affected / exposed	2 / 897 (0.22%)	5 / 1657 (0.30%)	0 / 178 (0.00%)
occurrences (all)	2	5	0
Depression suicidal			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Disruptive mood dysregulation disorder			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Sleep disorder			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Panic attack			

subjects affected / exposed	2 / 897 (0.22%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	3	1	0
Depression			
subjects affected / exposed	6 / 897 (0.67%)	14 / 1657 (0.84%)	2 / 178 (1.12%)
occurrences (all)	6	14	2
Confusional state			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Binge eating			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Insomnia			
subjects affected / exposed	3 / 897 (0.33%)	7 / 1657 (0.42%)	1 / 178 (0.56%)
occurrences (all)	3	7	1
Stress			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Tic			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Suicidal ideation			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Anger			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Acute stress disorder			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Irritability			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Mixed anxiety and depressive disorder			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0

Obsessive-compulsive disorder			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
School refusal			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Hallucination			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Investigations			
SARS-CoV-2 test positive			
subjects affected / exposed	6 / 897 (0.67%)	6 / 1657 (0.36%)	1 / 178 (0.56%)
occurrences (all)	6	6	1
Body temperature increased			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Cardiac murmur			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Computerised tomogram abdomen abnormal			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Haemoglobin decreased			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Heart rate irregular			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Liver function test increased			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Serum ferritin decreased			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Streptococcus test positive			

subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Thyroid hormones decreased			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	1 / 178 (0.56%)
occurrences (all)	0	0	1
Blood pressure increased			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Heart rate increased			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Red blood cell count increased			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Weight decreased			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Injury, poisoning and procedural complications			
Alcohol poisoning			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Arthropod bite			
subjects affected / exposed	0 / 897 (0.00%)	3 / 1657 (0.18%)	0 / 178 (0.00%)
occurrences (all)	0	3	0
Arthropod sting			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Ankle fracture			
subjects affected / exposed	0 / 897 (0.00%)	3 / 1657 (0.18%)	0 / 178 (0.00%)
occurrences (all)	0	3	0
Clavicle fracture			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Ligament sprain			

subjects affected / exposed	5 / 897 (0.56%)	14 / 1657 (0.84%)	1 / 178 (0.56%)
occurrences (all)	7	14	1
Contusion			
subjects affected / exposed	3 / 897 (0.33%)	8 / 1657 (0.48%)	0 / 178 (0.00%)
occurrences (all)	3	12	0
Eye abrasion			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Eye injury			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Facial bones fracture			
subjects affected / exposed	2 / 897 (0.22%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	2	1	0
Fall			
subjects affected / exposed	1 / 897 (0.11%)	3 / 1657 (0.18%)	2 / 178 (1.12%)
occurrences (all)	1	3	2
Fibula fracture			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	1 / 178 (0.56%)
occurrences (all)	0	0	1
Foot fracture			
subjects affected / exposed	2 / 897 (0.22%)	5 / 1657 (0.30%)	0 / 178 (0.00%)
occurrences (all)	2	5	0
Hand fracture			
subjects affected / exposed	3 / 897 (0.33%)	6 / 1657 (0.36%)	0 / 178 (0.00%)
occurrences (all)	3	7	0
Head injury			
subjects affected / exposed	1 / 897 (0.11%)	2 / 1657 (0.12%)	1 / 178 (0.56%)
occurrences (all)	1	2	1
Human bite			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Humerus fracture			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Infusion related reaction			

subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Joint dislocation			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	1 / 178 (0.56%)
occurrences (all)	0	2	1
Joint injury			
subjects affected / exposed	4 / 897 (0.45%)	4 / 1657 (0.24%)	0 / 178 (0.00%)
occurrences (all)	4	4	0
Ligament rupture			
subjects affected / exposed	1 / 897 (0.11%)	2 / 1657 (0.12%)	1 / 178 (0.56%)
occurrences (all)	1	2	1
Concussion			
subjects affected / exposed	3 / 897 (0.33%)	5 / 1657 (0.30%)	0 / 178 (0.00%)
occurrences (all)	3	5	0
Limb injury			
subjects affected / exposed	3 / 897 (0.33%)	5 / 1657 (0.30%)	0 / 178 (0.00%)
occurrences (all)	3	5	0
Skin abrasion			
subjects affected / exposed	3 / 897 (0.33%)	3 / 1657 (0.18%)	2 / 178 (1.12%)
occurrences (all)	3	3	2
Meniscus injury			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Muscle rupture			
subjects affected / exposed	1 / 897 (0.11%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	2	2	0
Muscle strain			
subjects affected / exposed	0 / 897 (0.00%)	3 / 1657 (0.18%)	0 / 178 (0.00%)
occurrences (all)	0	3	0
Musculoskeletal foreign body			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Nail injury			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Post procedural complication			

subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Post-traumatic neck syndrome			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Procedural complication			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Procedural dizziness			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Procedural nausea			
subjects affected / exposed	2 / 897 (0.22%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	2	2	0
Procedural pain			
subjects affected / exposed	0 / 897 (0.00%)	4 / 1657 (0.24%)	0 / 178 (0.00%)
occurrences (all)	0	4	0
Procedural vomiting			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Radius fracture			
subjects affected / exposed	1 / 897 (0.11%)	4 / 1657 (0.24%)	1 / 178 (0.56%)
occurrences (all)	1	4	1
Road traffic accident			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Scratch			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Lower limb fracture			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Skin laceration			
subjects affected / exposed	5 / 897 (0.56%)	5 / 1657 (0.30%)	1 / 178 (0.56%)
occurrences (all)	5	5	1
Thermal burn			

subjects affected / exposed	1 / 897 (0.11%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	1	2	0
Tibia fracture			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	1 / 178 (0.56%)
occurrences (all)	0	1	1
Torus fracture			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Traumatic haematoma			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Ulna fracture			
subjects affected / exposed	0 / 897 (0.00%)	4 / 1657 (0.24%)	1 / 178 (0.56%)
occurrences (all)	0	4	1
Upper limb fracture			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Vaccination complication			
subjects affected / exposed	2 / 897 (0.22%)	0 / 1657 (0.00%)	1 / 178 (0.56%)
occurrences (all)	2	0	1
Wrist fracture			
subjects affected / exposed	2 / 897 (0.22%)	9 / 1657 (0.54%)	0 / 178 (0.00%)
occurrences (all)	2	9	0
Tendon injury			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Anaesthetic complication			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Animal bite			
subjects affected / exposed	0 / 897 (0.00%)	4 / 1657 (0.24%)	0 / 178 (0.00%)
occurrences (all)	0	4	0
Animal scratch			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Tooth injury			

subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Bursa injury			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Compression fracture			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Ear canal injury			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Foreign body in respiratory tract			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Ligament injury			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Limb crushing injury			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Limb fracture			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal injury			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Nasal injury			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Post procedural haemorrhage			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Soft tissue injury			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Sports injury			

subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Stress fracture			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Sunburn			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Bone contusion			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Traumatic haemorrhage			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Wound			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Congenital, familial and genetic disorders			
Multiple endocrine neoplasia Type 1			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Rathke's cleft cyst			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Type V hyperlipidaemia			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Familial mediterranean fever			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Dermoid cyst			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Pectus excavatum			

subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Cardiac disorders			
Palpitations			
subjects affected / exposed	0 / 897 (0.00%)	4 / 1657 (0.24%)	0 / 178 (0.00%)
occurrences (all)	0	4	0
Supraventricular tachycardia			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Tachycardia paroxysmal			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Tachycardia			
subjects affected / exposed	0 / 897 (0.00%)	3 / 1657 (0.18%)	0 / 178 (0.00%)
occurrences (all)	0	3	0
Nervous system disorders			
Dyskinesia			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Dizziness			
subjects affected / exposed	6 / 897 (0.67%)	7 / 1657 (0.42%)	1 / 178 (0.56%)
occurrences (all)	8	7	1
Headache			
subjects affected / exposed	578 / 897 (64.44%)	929 / 1657 (56.07%)	97 / 178 (54.49%)
occurrences (all)	999	1578	148
Hypoaesthesia			
subjects affected / exposed	2 / 897 (0.22%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	2	1	0
Taste disorder			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Syncope			
subjects affected / exposed	1 / 897 (0.11%)	11 / 1657 (0.66%)	1 / 178 (0.56%)
occurrences (all)	1	11	1
Speech disorder			

subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	2	0	0
Lethargy			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Migraine			
subjects affected / exposed	3 / 897 (0.33%)	4 / 1657 (0.24%)	0 / 178 (0.00%)
occurrences (all)	3	4	0
Myoclonus			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Neuromuscular blockade			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Presyncope			
subjects affected / exposed	1 / 897 (0.11%)	5 / 1657 (0.30%)	0 / 178 (0.00%)
occurrences (all)	1	5	0
Psychomotor hyperactivity			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Seizure			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Restless legs syndrome			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Carpal tunnel syndrome			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Neuralgia			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Paraesthesia			

subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Sleep deficit			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Tension headache			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 897 (0.00%)	3 / 1657 (0.18%)	0 / 178 (0.00%)
occurrences (all)	0	4	0
Iron deficiency anaemia			
subjects affected / exposed	4 / 897 (0.45%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	4	1	0
Lymphadenitis			
subjects affected / exposed	2 / 897 (0.22%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	2	1	0
Lymphadenopathy			
subjects affected / exposed	5 / 897 (0.56%)	9 / 1657 (0.54%)	1 / 178 (0.56%)
occurrences (all)	6	9	1
Coagulopathy			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Increased tendency to bruise			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Ear and labyrinth disorders			
Hypoacusis			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Eustachian tube dysfunction			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Tympanic membrane perforation			

subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	4 / 897 (0.45%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	4	2	0
Tinnitus			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Cerumen impaction			
subjects affected / exposed	0 / 897 (0.00%)	3 / 1657 (0.18%)	0 / 178 (0.00%)
occurrences (all)	0	3	0
Ear discomfort			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Ear pain			
subjects affected / exposed	3 / 897 (0.33%)	6 / 1657 (0.36%)	0 / 178 (0.00%)
occurrences (all)	3	6	0
Excessive cerumen production			
subjects affected / exposed	0 / 897 (0.00%)	3 / 1657 (0.18%)	0 / 178 (0.00%)
occurrences (all)	0	3	0
External ear inflammation			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Motion sickness			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Tympanosclerosis			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Eye disorders			
Astigmatism			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Eye pain			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0

Blepharitis			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Glaucoma			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Keratitis			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Ocular hyperaemia			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Swelling of eyelid			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Eye irritation			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Conjunctivitis allergic			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Blindness transient			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Eye swelling			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Chalazion			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Conjunctival haemorrhage			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0

Eye inflammation			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Eye pruritus			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Eyelid exfoliation			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Eyelid ptosis			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Myopia			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	1 / 897 (0.11%)	3 / 1657 (0.18%)	0 / 178 (0.00%)
occurrences (all)	1	3	0
Abdominal distension			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Abdominal pain			
subjects affected / exposed	7 / 897 (0.78%)	13 / 1657 (0.78%)	1 / 178 (0.56%)
occurrences (all)	7	17	1
Abdominal pain lower			
subjects affected / exposed	3 / 897 (0.33%)	2 / 1657 (0.12%)	1 / 178 (0.56%)
occurrences (all)	3	2	1
Abdominal pain upper			
subjects affected / exposed	7 / 897 (0.78%)	18 / 1657 (1.09%)	2 / 178 (1.12%)
occurrences (all)	7	20	2
Anal fissure			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Colitis			

subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	3 / 897 (0.33%)	5 / 1657 (0.30%)	0 / 178 (0.00%)
occurrences (all)	3	5	0
Dental caries			
subjects affected / exposed	1 / 897 (0.11%)	3 / 1657 (0.18%)	0 / 178 (0.00%)
occurrences (all)	1	4	0
Diarrhoea			
subjects affected / exposed	14 / 897 (1.56%)	13 / 1657 (0.78%)	5 / 178 (2.81%)
occurrences (all)	15	13	5
Dyspepsia			
subjects affected / exposed	0 / 897 (0.00%)	5 / 1657 (0.30%)	1 / 178 (0.56%)
occurrences (all)	0	5	1
Enteritis			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Food poisoning			
subjects affected / exposed	0 / 897 (0.00%)	5 / 1657 (0.30%)	1 / 178 (0.56%)
occurrences (all)	0	5	1
Gastritis			
subjects affected / exposed	1 / 897 (0.11%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	1	2	0
Gastrooesophageal reflux disease			
subjects affected / exposed	2 / 897 (0.22%)	5 / 1657 (0.30%)	0 / 178 (0.00%)
occurrences (all)	2	5	0
Haematemesis			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	1 / 178 (0.56%)
occurrences (all)	0	0	1
Hyperchlorhydria			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Hypoaesthesia oral			

subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	1 / 178 (0.56%)
occurrences (all)	0	0	1
Irritable bowel syndrome			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Lip swelling			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Mouth ulceration			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	1 / 178 (0.56%)
occurrences (all)	1	0	1
Nausea			
subjects affected / exposed	245 / 897 (27.31%)	398 / 1657 (24.02%)	45 / 178 (25.28%)
occurrences (all)	324	500	59
Oral pain			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Pancreatitis relapsing			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Peptic ulcer			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Toothache			
subjects affected / exposed	1 / 897 (0.11%)	7 / 1657 (0.42%)	1 / 178 (0.56%)
occurrences (all)	1	7	1
Vomiting			
subjects affected / exposed	6 / 897 (0.67%)	12 / 1657 (0.72%)	1 / 178 (0.56%)
occurrences (all)	6	12	1
Oral pruritus			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Aphthous ulcer			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0

Coeliac disease			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Embedded tooth			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Eructation			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Flatulence			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Palatal disorder			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Tongue discolouration			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Transient lingual papillitis			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Gingival pain			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Hepatobiliary disorders			
Hepatic steatosis			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Skin and subcutaneous tissue disorders			
Pityriasis			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Acne			
subjects affected / exposed	8 / 897 (0.89%)	12 / 1657 (0.72%)	1 / 178 (0.56%)
occurrences (all)	8	14	1
Cold urticaria			

subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Dermatitis			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Dermatitis allergic			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Dermatitis atopic			
subjects affected / exposed	1 / 897 (0.11%)	4 / 1657 (0.24%)	0 / 178 (0.00%)
occurrences (all)	1	4	0
Dermatitis contact			
subjects affected / exposed	3 / 897 (0.33%)	4 / 1657 (0.24%)	0 / 178 (0.00%)
occurrences (all)	3	5	0
Eczema			
subjects affected / exposed	4 / 897 (0.45%)	5 / 1657 (0.30%)	0 / 178 (0.00%)
occurrences (all)	4	6	0
Erythema			
subjects affected / exposed	3 / 897 (0.33%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	4	0	0
Hand dermatitis			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Hyperhidrosis			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Ingrowing nail			
subjects affected / exposed	3 / 897 (0.33%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	3	1	0
Miliaria			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	1 / 178 (0.56%)
occurrences (all)	0	0	1
Pain of skin			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Pruritus			

subjects affected / exposed	3 / 897 (0.33%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	3	1	0
Rash			
subjects affected / exposed	3 / 897 (0.33%)	13 / 1657 (0.78%)	0 / 178 (0.00%)
occurrences (all)	3	13	0
Rash macular			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Rash maculo-papular			
subjects affected / exposed	2 / 897 (0.22%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	2	1	0
Rash pruritic			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	2	0	0
Skin lesion			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	2 / 897 (0.22%)	4 / 1657 (0.24%)	1 / 178 (0.56%)
occurrences (all)	2	4	1
Alopecia			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Dermatitis acneiform			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Drug eruption			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Nail disorder			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Psoriasis			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Rash erythematous			

subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Seborrhoeic dermatitis			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Skin induration			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Urticaria chronic			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 897 (0.00%)	3 / 1657 (0.18%)	0 / 178 (0.00%)
occurrences (all)	0	5	0
Haematuria			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Hydronephrosis			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Nephritis			
subjects affected / exposed	3 / 897 (0.33%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	3	0	0
Nephrolithiasis			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Pollakiuria			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Urinary retention			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Urinary tract inflammation			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0

Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Thyroid stimulating hormone deficiency			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Growth hormone deficiency			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Hyperthyroidism			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Thyroid cyst			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal and connective tissue disorders			
Joint swelling			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 897 (0.00%)	3 / 1657 (0.18%)	0 / 178 (0.00%)
occurrences (all)	0	3	0
Growing pains			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Foot deformity			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	1 / 178 (0.56%)
occurrences (all)	0	0	1
Flank pain			
subjects affected / exposed	1 / 897 (0.11%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	1	2	0
Epiphysiolysis			

subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	7 / 897 (0.78%)	15 / 1657 (0.91%)	2 / 178 (1.12%)
occurrences (all)	7	15	2
Axillary mass			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Arthritis			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Arthralgia			
subjects affected / exposed	154 / 897 (17.17%)	236 / 1657 (14.24%)	25 / 178 (14.04%)
occurrences (all)	205	290	30
Joint warmth			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Knee deformity			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Muscle swelling			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Muscle tightness			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Joint hyperextension			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Tenosynovitis			
subjects affected / exposed	1 / 897 (0.11%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	1	2	0
Tendon pain			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0

Temporomandibular joint syndrome			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Spinal pain			
subjects affected / exposed	2 / 897 (0.22%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	2	0	0
Sever's disease			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Rotator cuff syndrome			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Pain in extremity			
subjects affected / exposed	5 / 897 (0.56%)	9 / 1657 (0.54%)	1 / 178 (0.56%)
occurrences (all)	5	12	1
Osteochondrosis			
subjects affected / exposed	4 / 897 (0.45%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	4	0	0
Neck pain			
subjects affected / exposed	1 / 897 (0.11%)	3 / 1657 (0.18%)	0 / 178 (0.00%)
occurrences (all)	1	3	0
Neck mass			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Myositis			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Myalgia			
subjects affected / exposed	240 / 897 (26.76%)	384 / 1657 (23.17%)	30 / 178 (16.85%)
occurrences (all)	325	500	35
Musculoskeletal chest pain			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Rhabdomyolysis			

subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Bone pain			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Coccydynia			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Costochondritis			
subjects affected / exposed	0 / 897 (0.00%)	3 / 1657 (0.18%)	0 / 178 (0.00%)
occurrences (all)	0	3	0
Joint effusion			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Myokymia			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Pain in jaw			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Sacral pain			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Scoliosis			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Short stature			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Spinal flattening			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Synovial cyst			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Tendonitis			

subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Torticollis			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Infections and infestations			
Bacterial vaginosis			
subjects affected / exposed	1 / 897 (0.11%)	3 / 1657 (0.18%)	0 / 178 (0.00%)
occurrences (all)	1	3	0
Acarodermatitis			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Acute sinusitis			
subjects affected / exposed	0 / 897 (0.00%)	4 / 1657 (0.24%)	0 / 178 (0.00%)
occurrences (all)	0	4	0
Adenovirus infection			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Asymptomatic COVID-19			
subjects affected / exposed	3 / 897 (0.33%)	3 / 1657 (0.18%)	0 / 178 (0.00%)
occurrences (all)	3	3	0
Enterovirus infection			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Enterobiasis			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Eye infection			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Eyelid infection			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Folliculitis			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0

Gastroenteritis			
subjects affected / exposed	6 / 897 (0.67%)	16 / 1657 (0.97%)	0 / 178 (0.00%)
occurrences (all)	6	16	0
Body tinea			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Bronchitis			
subjects affected / exposed	2 / 897 (0.22%)	4 / 1657 (0.24%)	0 / 178 (0.00%)
occurrences (all)	2	4	0
Bullous impetigo			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
COVID-19			
subjects affected / exposed	93 / 897 (10.37%)	195 / 1657 (11.77%)	26 / 178 (14.61%)
occurrences (all)	96	198	26
COVID-19 pneumonia			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Chlamydial infection			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Coronavirus infection			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Cystitis			
subjects affected / exposed	1 / 897 (0.11%)	5 / 1657 (0.30%)	1 / 178 (0.56%)
occurrences (all)	1	5	1
Ear infection			
subjects affected / exposed	3 / 897 (0.33%)	2 / 1657 (0.12%)	1 / 178 (0.56%)
occurrences (all)	3	2	1
Endometritis			

subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Erythema migrans			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis viral			
subjects affected / exposed	3 / 897 (0.33%)	7 / 1657 (0.42%)	0 / 178 (0.00%)
occurrences (all)	3	7	0
Genital herpes			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Gingivitis			
subjects affected / exposed	2 / 897 (0.22%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	2	1	0
Infected bite			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	1 / 178 (0.56%)
occurrences (all)	0	0	1
Herpes zoster			
subjects affected / exposed	1 / 897 (0.11%)	3 / 1657 (0.18%)	1 / 178 (0.56%)
occurrences (all)	1	3	1
Hordeolum			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Impetigo			
subjects affected / exposed	2 / 897 (0.22%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	2	2	0
Helicobacter gastritis			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Infectious mononucleosis			
subjects affected / exposed	2 / 897 (0.22%)	3 / 1657 (0.18%)	2 / 178 (1.12%)
occurrences (all)	2	3	2
Pharyngitis streptococcal			
subjects affected / exposed	2 / 897 (0.22%)	6 / 1657 (0.36%)	1 / 178 (0.56%)
occurrences (all)	2	6	1
Localised infection			

subjects affected / exposed	1 / 897 (0.11%)	4 / 1657 (0.24%)	0 / 178 (0.00%)
occurrences (all)	1	4	0
Lower respiratory tract infection			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Lyme disease			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Mycoplasma genitalium infection			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Nasopharyngitis			
subjects affected / exposed	29 / 897 (3.23%)	60 / 1657 (3.62%)	11 / 178 (6.18%)
occurrences (all)	33	65	11
Onychomycosis			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Oral herpes			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Otitis externa			
subjects affected / exposed	4 / 897 (0.45%)	10 / 1657 (0.60%)	0 / 178 (0.00%)
occurrences (all)	5	10	0
Otitis media			
subjects affected / exposed	6 / 897 (0.67%)	6 / 1657 (0.36%)	0 / 178 (0.00%)
occurrences (all)	6	6	0
Otitis media acute			
subjects affected / exposed	3 / 897 (0.33%)	3 / 1657 (0.18%)	1 / 178 (0.56%)
occurrences (all)	4	3	1
Otosalpingitis			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Paronychia			
subjects affected / exposed	2 / 897 (0.22%)	5 / 1657 (0.30%)	0 / 178 (0.00%)
occurrences (all)	2	5	0
Parotitis			

subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Pelvic inflammatory disease			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Pharyngitis			
subjects affected / exposed	8 / 897 (0.89%)	28 / 1657 (1.69%)	2 / 178 (1.12%)
occurrences (all)	9	30	2
Influenza			
subjects affected / exposed	10 / 897 (1.11%)	22 / 1657 (1.33%)	1 / 178 (0.56%)
occurrences (all)	10	22	1
Postoperative wound infection			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Pulpitis dental			
subjects affected / exposed	2 / 897 (0.22%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	2	1	0
Respiratory tract infection			
subjects affected / exposed	1 / 897 (0.11%)	4 / 1657 (0.24%)	0 / 178 (0.00%)
occurrences (all)	1	4	0
Respiratory tract infection bacterial			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Respiratory tract infection viral			
subjects affected / exposed	2 / 897 (0.22%)	11 / 1657 (0.66%)	2 / 178 (1.12%)
occurrences (all)	3	14	2
Rhinitis			
subjects affected / exposed	4 / 897 (0.45%)	6 / 1657 (0.36%)	2 / 178 (1.12%)
occurrences (all)	4	6	2
Rhinovirus infection			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Sialoadenitis			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Sinusitis			

subjects affected / exposed	4 / 897 (0.45%)	3 / 1657 (0.18%)	2 / 178 (1.12%)
occurrences (all)	4	3	2
Skin infection			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Soft tissue infection			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Streptococcal infection			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Suspected COVID-19			
subjects affected / exposed	5 / 897 (0.56%)	10 / 1657 (0.60%)	0 / 178 (0.00%)
occurrences (all)	5	11	0
Tinea versicolour			
subjects affected / exposed	1 / 897 (0.11%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	1	2	0
Tonsillitis			
subjects affected / exposed	10 / 897 (1.11%)	20 / 1657 (1.21%)	5 / 178 (2.81%)
occurrences (all)	10	22	6
Tonsillitis streptococcal			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Tooth abscess			
subjects affected / exposed	1 / 897 (0.11%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	1	2	0
Tooth infection			
subjects affected / exposed	1 / 897 (0.11%)	2 / 1657 (0.12%)	1 / 178 (0.56%)
occurrences (all)	1	2	1
Yersinia infection			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Tracheitis			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Trichomoniasis			

subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	1 / 178 (0.56%)
occurrences (all)	0	0	1
Upper respiratory tract infection			
subjects affected / exposed	35 / 897 (3.90%)	71 / 1657 (4.28%)	6 / 178 (3.37%)
occurrences (all)	38	74	6
Upper respiratory tract infection bacterial			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Urinary tract infection			
subjects affected / exposed	9 / 897 (1.00%)	13 / 1657 (0.78%)	3 / 178 (1.69%)
occurrences (all)	11	17	3
Vaginal infection			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	1 / 178 (0.56%)
occurrences (all)	0	1	2
Varicella			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Viral infection			
subjects affected / exposed	5 / 897 (0.56%)	7 / 1657 (0.42%)	0 / 178 (0.00%)
occurrences (all)	5	8	0
Viral pharyngitis			
subjects affected / exposed	1 / 897 (0.11%)	3 / 1657 (0.18%)	0 / 178 (0.00%)
occurrences (all)	1	3	0
Viral upper respiratory tract infection			
subjects affected / exposed	3 / 897 (0.33%)	9 / 1657 (0.54%)	0 / 178 (0.00%)
occurrences (all)	3	9	0
Vulvovaginal candidiasis			
subjects affected / exposed	2 / 897 (0.22%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	2	0	0
Vulvovaginal mycotic infection			
subjects affected / exposed	1 / 897 (0.11%)	3 / 1657 (0.18%)	0 / 178 (0.00%)
occurrences (all)	1	3	0
Wound infection			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	1 / 178 (0.56%)
occurrences (all)	0	0	1

Laryngitis			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Conjunctivitis			
subjects affected / exposed	0 / 897 (0.00%)	9 / 1657 (0.54%)	0 / 178 (0.00%)
occurrences (all)	0	9	0
Conjunctivitis viral			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Ear lobe infection			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Fungal foot infection			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Fungal skin infection			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Gastrointestinal viral infection			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Hand-foot-and-mouth disease			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Helminthic infection			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Herpes simplex			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Pericoronitis			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Parasitic gastroenteritis			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0

Post-acute COVID-19 syndrome			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Skin bacterial infection			
subjects affected / exposed	0 / 897 (0.00%)	3 / 1657 (0.18%)	0 / 178 (0.00%)
occurrences (all)	0	3	0
Subcutaneous abscess			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Tinea pedis			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Vaccination site cellulitis			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Vaccination site pustule			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Vulvovaginitis			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Laryngotracheitis obstructive			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Molluscum contagiosum			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Oral candidiasis			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Pharyngotonsillitis			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0

Metabolism and nutrition disorders			
Insulin resistance			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Iron deficiency			
subjects affected / exposed	1 / 897 (0.11%)	6 / 1657 (0.36%)	0 / 178 (0.00%)
occurrences (all)	1	6	0
Lactose intolerance			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Obesity			
subjects affected / exposed	2 / 897 (0.22%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	2	2	0
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Vitamin B complex deficiency			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Vitamin B12 deficiency			
subjects affected / exposed	0 / 897 (0.00%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	0	2	0
Abnormal loss of weight			
subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Folate deficiency			
subjects affected / exposed	2 / 897 (0.22%)	2 / 1657 (0.12%)	0 / 178 (0.00%)
occurrences (all)	2	2	0
Glucose tolerance impaired			
subjects affected / exposed	2 / 897 (0.22%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	2	0	0
Gluten sensitivity			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	1 / 178 (0.56%)
occurrences (all)	0	1	1
Hypercholesterolaemia			

subjects affected / exposed	1 / 897 (0.11%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	1	1	0
Hyperlipidaemia			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Hyponatraemia			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Zinc deficiency			
subjects affected / exposed	0 / 897 (0.00%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	0	0	0
Vitamin D deficiency			
subjects affected / exposed	1 / 897 (0.11%)	0 / 1657 (0.00%)	0 / 178 (0.00%)
occurrences (all)	1	0	0
Decreased appetite			
subjects affected / exposed	0 / 897 (0.00%)	3 / 1657 (0.18%)	0 / 178 (0.00%)
occurrences (all)	0	3	0
Haemochromatosis			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Hypertriglyceridaemia			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Hypoglycaemia			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0
Hypovitaminosis			
subjects affected / exposed	0 / 897 (0.00%)	1 / 1657 (0.06%)	0 / 178 (0.00%)
occurrences (all)	0	1	0

Non-serious adverse events	MenB_0_6 Group		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	872 / 906 (96.25%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			

subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Skin papilloma			
subjects affected / exposed	2 / 906 (0.22%)		
occurrences (all)	2		
Benign soft tissue neoplasm			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Fibroadenoma of breast			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Lipoma			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Melanocytic naevus			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Vascular disorders			
Pallor			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Hypertension			
subjects affected / exposed	2 / 906 (0.22%)		
occurrences (all)	2		
Haematoma			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Hot flush			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Varicose vein			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Hypotension			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		

Hyperaemia			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Peripheral venous disease			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Orthostatic hypotension			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
General disorders and administration site conditions			
Induration			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Administration site erythema			
subjects affected / exposed	157 / 906 (17.33%)		
occurrences (all)	203		
Administration site induration			
subjects affected / exposed	113 / 906 (12.47%)		
occurrences (all)	142		
Administration site pain			
subjects affected / exposed	853 / 906 (94.15%)		
occurrences (all)	1768		
Administration site swelling			
subjects affected / exposed	158 / 906 (17.44%)		
occurrences (all)	200		
Asthenia			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Chest pain			
subjects affected / exposed	2 / 906 (0.22%)		
occurrences (all)	2		
Chills			
subjects affected / exposed	3 / 906 (0.33%)		
occurrences (all)	4		
Cyst			

subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Fatigue				
subjects affected / exposed	579 / 906 (63.91%)			
occurrences (all)	1005			
Feeling hot				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Influenza like illness				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	3			
Thirst				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Injection site haematoma				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Injection site hypoaesthesia				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Injection site induration				
subjects affected / exposed	5 / 906 (0.55%)			
occurrences (all)	5			
Injection site mass				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Injection site pain				
subjects affected / exposed	8 / 906 (0.88%)			
occurrences (all)	8			
Injection site pruritus				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	2			
Injection site rash				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Injection site swelling				

subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Injection site warmth				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Malaise				
subjects affected / exposed	3 / 906 (0.33%)			
occurrences (all)	3			
Non-cardiac chest pain				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Pain				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Peripheral swelling				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Pyrexia				
subjects affected / exposed	59 / 906 (6.51%)			
occurrences (all)	62			
Swelling				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Injection site bruising				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Vaccination site pain				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Vaccination site urticaria				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Vaccination site warmth				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Vessel puncture site pain				

subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Vaccination site pruritus				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Medical device pain				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Axillary pain				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Chest discomfort				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Discomfort				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Feeling cold				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Injection site discomfort				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Injection site eczema				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Injection site erythema				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Injection site haemorrhage				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Injection site papule				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Injection site paraesthesia				

subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Injection site reaction			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Oedema peripheral			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Vaccination site bruising			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Vaccination site erythema			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Vaccination site reaction			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Swelling face			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Immune system disorders			
Anaphylactoid reaction			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Drug hypersensitivity			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Food allergy			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Hypersensitivity			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Multiple allergies			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		

Seasonal allergy subjects affected / exposed occurrences (all)	7 / 906 (0.77%) 7		
Allergy to animal subjects affected / exposed occurrences (all)	0 / 906 (0.00%) 0		
Allergy to arthropod sting subjects affected / exposed occurrences (all)	0 / 906 (0.00%) 0		
Dust allergy subjects affected / exposed occurrences (all)	0 / 906 (0.00%) 0		
Social circumstances Menarche subjects affected / exposed occurrences (all)	0 / 906 (0.00%) 0		
Reproductive system and breast disorders Heavy menstrual bleeding subjects affected / exposed occurrences (all)	1 / 906 (0.11%) 1		
Breast cyst subjects affected / exposed occurrences (all)	0 / 906 (0.00%) 0		
Breast inflammation subjects affected / exposed occurrences (all)	1 / 906 (0.11%) 1		
Breast mass subjects affected / exposed occurrences (all)	1 / 906 (0.11%) 1		
Breast tenderness subjects affected / exposed occurrences (all)	0 / 906 (0.00%) 0		
Dysmenorrhoea subjects affected / exposed occurrences (all)	10 / 906 (1.10%) 10		
Endometriosis			

subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Intermenstrual bleeding				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Nipple enlargement				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Ovarian cyst				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Penile rash				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Premenstrual syndrome				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Testicular pain				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Vaginal haemorrhage				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Menstruation irregular				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Abnormal uterine bleeding				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Amenorrhoea				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Bartholin's cyst				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Breast discharge				

subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Breast haematoma			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Breast pain			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Menstruation delayed			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Premenstrual pain			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Uterine spasm			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Rhinorrhoea			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Asthma			
subjects affected / exposed	6 / 906 (0.66%)		
occurrences (all)	8		
Cough			
subjects affected / exposed	3 / 906 (0.33%)		
occurrences (all)	4		
Dyspnoea			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Epistaxis			
subjects affected / exposed	3 / 906 (0.33%)		
occurrences (all)	3		
Nasal congestion			

subjects affected / exposed	6 / 906 (0.66%)			
occurrences (all)	6			
Oropharyngeal pain				
subjects affected / exposed	11 / 906 (1.21%)			
occurrences (all)	12			
Respiratory tract congestion				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Rhinalgia				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Rhinitis allergic				
subjects affected / exposed	3 / 906 (0.33%)			
occurrences (all)	3			
Sneezing				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Upper-airway cough syndrome				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Wheezing				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Tonsillolith				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Bronchial hyperreactivity				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Increased upper airway secretion				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Pleuritic pain				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Respiratory disorder				

subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Throat clearing			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Hiccups			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Psychiatric disorders			
Anxiety			
subjects affected / exposed	8 / 906 (0.88%)		
occurrences (all)	8		
Anorexia nervosa			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Aggression			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Adjustment disorder with depressed mood			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Adjustment disorder			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Attention deficit hyperactivity disorder			
subjects affected / exposed	4 / 906 (0.44%)		
occurrences (all)	4		
Anxiety disorder			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Depression suicidal			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Disruptive mood dysregulation disorder			

subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Sleep disorder				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Panic attack				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Depression				
subjects affected / exposed	4 / 906 (0.44%)			
occurrences (all)	4			
Confusional state				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Binge eating				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Insomnia				
subjects affected / exposed	3 / 906 (0.33%)			
occurrences (all)	3			
Stress				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Tic				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Suicidal ideation				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Anger				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Acute stress disorder				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Irritability				

subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Mixed anxiety and depressive disorder			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Obsessive-compulsive disorder			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
School refusal			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Hallucination			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Investigations			
SARS-CoV-2 test positive			
subjects affected / exposed	7 / 906 (0.77%)		
occurrences (all)	7		
Body temperature increased			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Cardiac murmur			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Computerised tomogram abdomen abnormal			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Haemoglobin decreased			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Heart rate irregular			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Liver function test increased			

subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Serum ferritin decreased			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Streptococcus test positive			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Thyroid hormones decreased			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Blood pressure increased			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Heart rate increased			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Red blood cell count increased			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Weight decreased			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Injury, poisoning and procedural complications			
Alcohol poisoning			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Arthropod bite			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Arthropod sting			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Ankle fracture			

subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Clavicle fracture				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Ligament sprain				
subjects affected / exposed	16 / 906 (1.77%)			
occurrences (all)	17			
Contusion				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Eye abrasion				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Eye injury				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Facial bones fracture				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Fall				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Fibula fracture				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Foot fracture				
subjects affected / exposed	5 / 906 (0.55%)			
occurrences (all)	6			
Hand fracture				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Head injury				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Human bite				

subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Humerus fracture				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Infusion related reaction				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Joint dislocation				
subjects affected / exposed	4 / 906 (0.44%)			
occurrences (all)	4			
Joint injury				
subjects affected / exposed	3 / 906 (0.33%)			
occurrences (all)	3			
Ligament rupture				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Concussion				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Limb injury				
subjects affected / exposed	5 / 906 (0.55%)			
occurrences (all)	5			
Skin abrasion				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	3			
Meniscus injury				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Muscle rupture				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Muscle strain				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Musculoskeletal foreign body				

subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Nail injury				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Post procedural complication				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Post-traumatic neck syndrome				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Procedural complication				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Procedural dizziness				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Procedural nausea				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Procedural pain				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Procedural vomiting				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Radius fracture				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Road traffic accident				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Scratch				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Lower limb fracture				

subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Skin laceration				
subjects affected / exposed	5 / 906 (0.55%)			
occurrences (all)	5			
Thermal burn				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Tibia fracture				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Torus fracture				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Traumatic haematoma				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Ulna fracture				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Upper limb fracture				
subjects affected / exposed	4 / 906 (0.44%)			
occurrences (all)	5			
Vaccination complication				
subjects affected / exposed	3 / 906 (0.33%)			
occurrences (all)	3			
Wrist fracture				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Tendon injury				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Anaesthetic complication				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Animal bite				

subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Animal scratch				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Tooth injury				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Bursa injury				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Compression fracture				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Ear canal injury				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Foreign body in respiratory tract				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Ligament injury				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Limb crushing injury				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Limb fracture				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Musculoskeletal injury				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Nasal injury				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Post procedural haemorrhage				

subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Soft tissue injury			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Sports injury			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Stress fracture			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Sunburn			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Bone contusion			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Traumatic haemorrhage			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Wound			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Congenital, familial and genetic disorders			
Multiple endocrine neoplasia Type 1			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Rathke's cleft cyst			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Type V hyperlipidaemia			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Familial mediterranean fever			

subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Dermoid cyst			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Pectus excavatum			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Cardiac disorders			
Palpitations			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Supraventricular tachycardia			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Tachycardia paroxysmal			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Tachycardia			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Nervous system disorders			
Dyskinesia			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Dizziness			
subjects affected / exposed	6 / 906 (0.66%)		
occurrences (all)	6		
Headache			
subjects affected / exposed	525 / 906 (57.95%)		
occurrences (all)	874		
Hypoaesthesia			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Taste disorder			

subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Syncope				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Speech disorder				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Somnolence				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Lethargy				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Migraine				
subjects affected / exposed	5 / 906 (0.55%)			
occurrences (all)	5			
Myoclonus				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Neuromuscular blockade				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Presyncope				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Psychomotor hyperactivity				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Seizure				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Restless legs syndrome				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Carpal tunnel syndrome				

subjects affected / exposed occurrences (all)	0 / 906 (0.00%) 0		
Neuralgia subjects affected / exposed occurrences (all)	0 / 906 (0.00%) 0		
Paraesthesia subjects affected / exposed occurrences (all)	0 / 906 (0.00%) 0		
Sleep deficit subjects affected / exposed occurrences (all)	0 / 906 (0.00%) 0		
Tension headache subjects affected / exposed occurrences (all)	0 / 906 (0.00%) 0		
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	1 / 906 (0.11%) 1		
Iron deficiency anaemia subjects affected / exposed occurrences (all)	1 / 906 (0.11%) 1		
Lymphadenitis subjects affected / exposed occurrences (all)	1 / 906 (0.11%) 1		
Lymphadenopathy subjects affected / exposed occurrences (all)	7 / 906 (0.77%) 7		
Coagulopathy subjects affected / exposed occurrences (all)	0 / 906 (0.00%) 0		
Increased tendency to bruise subjects affected / exposed occurrences (all)	0 / 906 (0.00%) 0		
Ear and labyrinth disorders Hypoacusis			

subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Eustachian tube dysfunction			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Tympanic membrane perforation			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Vertigo			
subjects affected / exposed	3 / 906 (0.33%)		
occurrences (all)	3		
Tinnitus			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Cerumen impaction			
subjects affected / exposed	2 / 906 (0.22%)		
occurrences (all)	2		
Ear discomfort			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Ear pain			
subjects affected / exposed	2 / 906 (0.22%)		
occurrences (all)	2		
Excessive cerumen production			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
External ear inflammation			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Motion sickness			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Tympanosclerosis			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Eye disorders			

Astigmatism				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Eye pain				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Blepharitis				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Glaucoma				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Keratitis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Ocular hyperaemia				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Swelling of eyelid				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Vision blurred				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Eye irritation				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Conjunctivitis allergic				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Blindness transient				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Eye swelling				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			

Chalazion				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Conjunctival haemorrhage				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Eye inflammation				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Eye pruritus				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Eyelid exfoliation				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Eyelid ptosis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Myopia				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Gastrointestinal disorders				
Abdominal discomfort				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Abdominal distension				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Abdominal pain				
subjects affected / exposed	11 / 906 (1.21%)			
occurrences (all)	12			
Abdominal pain lower				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Abdominal pain upper				

subjects affected / exposed	9 / 906 (0.99%)			
occurrences (all)	10			
Anal fissure				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Colitis				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Constipation				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Dental caries				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Diarrhoea				
subjects affected / exposed	16 / 906 (1.77%)			
occurrences (all)	19			
Dyspepsia				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Enteritis				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Food poisoning				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Gastritis				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Gastrooesophageal reflux disease				
subjects affected / exposed	4 / 906 (0.44%)			
occurrences (all)	4			
Haematemesis				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Haemorrhoids				

subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Hyperchlorhydria				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Hypoaesthesia oral				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Irritable bowel syndrome				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Lip swelling				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Mouth ulceration				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Nausea				
subjects affected / exposed	204 / 906 (22.52%)			
occurrences (all)	262			
Oral pain				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Pancreatitis relapsing				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Peptic ulcer				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Toothache				
subjects affected / exposed	5 / 906 (0.55%)			
occurrences (all)	6			
Vomiting				
subjects affected / exposed	11 / 906 (1.21%)			
occurrences (all)	11			
Oral pruritus				

subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Aphthous ulcer			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Coeliac disease			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Embedded tooth			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Eructation			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Flatulence			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Palatal disorder			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Tongue discolouration			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Transient lingual papillitis			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Gingival pain			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Hepatobiliary disorders			
Hepatic steatosis			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Skin and subcutaneous tissue disorders			
Pityriasis			

subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Acne				
subjects affected / exposed	7 / 906 (0.77%)			
occurrences (all)	7			
Cold urticaria				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Dermatitis				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Dermatitis allergic				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Dermatitis atopic				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Dermatitis contact				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Eczema				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Erythema				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Hand dermatitis				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Hyperhidrosis				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Ingrowing nail				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Miliaria				

subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Pain of skin				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Pruritus				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Rash				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Rash macular				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Rash maculo-papular				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Rash pruritic				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Skin lesion				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Urticaria				
subjects affected / exposed	3 / 906 (0.33%)			
occurrences (all)	3			
Alopecia				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Dermatitis acneiform				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Drug eruption				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Nail disorder				

subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Psoriasis			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Rash erythematous			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Seborrhoeic dermatitis			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Skin induration			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Urticaria chronic			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Haematuria			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Hydronephrosis			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Nephritis			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Nephrolithiasis			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Pollakiuria			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		

Urinary retention subjects affected / exposed occurrences (all)	1 / 906 (0.11%) 1		
Urinary tract inflammation subjects affected / exposed occurrences (all)	1 / 906 (0.11%) 1		
Endocrine disorders			
Hypothyroidism subjects affected / exposed occurrences (all)	1 / 906 (0.11%) 1		
Thyroid stimulating hormone deficiency subjects affected / exposed occurrences (all)	0 / 906 (0.00%) 0		
Growth hormone deficiency subjects affected / exposed occurrences (all)	0 / 906 (0.00%) 0		
Hyperthyroidism subjects affected / exposed occurrences (all)	0 / 906 (0.00%) 0		
Thyroid cyst subjects affected / exposed occurrences (all)	0 / 906 (0.00%) 0		
Musculoskeletal and connective tissue disorders			
Joint swelling subjects affected / exposed occurrences (all)	1 / 906 (0.11%) 1		
Muscular weakness subjects affected / exposed occurrences (all)	3 / 906 (0.33%) 3		
Intervertebral disc protrusion subjects affected / exposed occurrences (all)	1 / 906 (0.11%) 1		
Growing pains subjects affected / exposed occurrences (all)	0 / 906 (0.00%) 0		
Foot deformity			

subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Flank pain				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Epiphysiolysis				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Back pain				
subjects affected / exposed	15 / 906 (1.66%)			
occurrences (all)	15			
Axillary mass				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Arthritis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Arthralgia				
subjects affected / exposed	127 / 906 (14.02%)			
occurrences (all)	163			
Joint warmth				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Knee deformity				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Muscle swelling				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Muscle tightness				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Joint hyperextension				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Tenosynovitis				

subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Tendon pain				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Temporomandibular joint syndrome				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Spinal pain				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Sever's disease				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Rotator cuff syndrome				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Pain in extremity				
subjects affected / exposed	11 / 906 (1.21%)			
occurrences (all)	11			
Osteochondrosis				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Neck pain				
subjects affected / exposed	3 / 906 (0.33%)			
occurrences (all)	3			
Neck mass				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Myositis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Myalgia				
subjects affected / exposed	209 / 906 (23.07%)			
occurrences (all)	276			
Musculoskeletal chest pain				

subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Rhabdomyolysis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Bone pain				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Coccydynia				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Costochondritis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Joint effusion				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Myokymia				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Pain in jaw				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Sacral pain				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Scoliosis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Short stature				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Spinal flattening				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Synovial cyst				

subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Tendonitis			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Torticollis			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Bacterial vaginosis			
subjects affected / exposed	2 / 906 (0.22%)		
occurrences (all)	2		
Acarodermatitis			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Acute sinusitis			
subjects affected / exposed	4 / 906 (0.44%)		
occurrences (all)	4		
Adenovirus infection			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Asymptomatic COVID-19			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Enterovirus infection			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Enterobiasis			
subjects affected / exposed	2 / 906 (0.22%)		
occurrences (all)	2		
Eye infection			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Eyelid infection			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		

Folliculitis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Gastroenteritis				
subjects affected / exposed	4 / 906 (0.44%)			
occurrences (all)	5			
Body tinea				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Bronchitis				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Bullous impetigo				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
COVID-19				
subjects affected / exposed	107 / 906 (11.81%)			
occurrences (all)	111			
COVID-19 pneumonia				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Cellulitis				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Chlamydial infection				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Coronavirus infection				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Cystitis				
subjects affected / exposed	3 / 906 (0.33%)			
occurrences (all)	3			
Ear infection				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			

Endometritis				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Erythema migrans				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Gastroenteritis viral				
subjects affected / exposed	6 / 906 (0.66%)			
occurrences (all)	6			
Genital herpes				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Gingivitis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Infected bite				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Herpes zoster				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Hordeolum				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Impetigo				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Helicobacter gastritis				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Infectious mononucleosis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Pharyngitis streptococcal				
subjects affected / exposed	4 / 906 (0.44%)			
occurrences (all)	4			

Localised infection				
subjects affected / exposed	4 / 906 (0.44%)			
occurrences (all)	4			
Lower respiratory tract infection				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Lyme disease				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Mycoplasma genitalium infection				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Nasopharyngitis				
subjects affected / exposed	37 / 906 (4.08%)			
occurrences (all)	42			
Onychomycosis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Oral herpes				
subjects affected / exposed	5 / 906 (0.55%)			
occurrences (all)	6			
Otitis externa				
subjects affected / exposed	4 / 906 (0.44%)			
occurrences (all)	4			
Otitis media				
subjects affected / exposed	3 / 906 (0.33%)			
occurrences (all)	3			
Otitis media acute				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	2			
Otosalpingitis				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Paronychia				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			

Parotitis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Pelvic inflammatory disease				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Pharyngitis				
subjects affected / exposed	19 / 906 (2.10%)			
occurrences (all)	24			
Influenza				
subjects affected / exposed	11 / 906 (1.21%)			
occurrences (all)	12			
Postoperative wound infection				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Pulpitis dental				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Respiratory tract infection				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Respiratory tract infection bacterial				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Respiratory tract infection viral				
subjects affected / exposed	7 / 906 (0.77%)			
occurrences (all)	8			
Rhinitis				
subjects affected / exposed	8 / 906 (0.88%)			
occurrences (all)	8			
Rhinovirus infection				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Sialoadenitis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			

Sinusitis				
subjects affected / exposed	3 / 906 (0.33%)			
occurrences (all)	3			
Skin infection				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Soft tissue infection				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Streptococcal infection				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Suspected COVID-19				
subjects affected / exposed	6 / 906 (0.66%)			
occurrences (all)	6			
Tinea versicolour				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Tonsillitis				
subjects affected / exposed	15 / 906 (1.66%)			
occurrences (all)	17			
Tonsillitis streptococcal				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Tooth abscess				
subjects affected / exposed	3 / 906 (0.33%)			
occurrences (all)	3			
Tooth infection				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Yersinia infection				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Tracheitis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			

Trichomoniasis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Upper respiratory tract infection				
subjects affected / exposed	42 / 906 (4.64%)			
occurrences (all)	46			
Upper respiratory tract infection bacterial				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Urinary tract infection				
subjects affected / exposed	9 / 906 (0.99%)			
occurrences (all)	10			
Vaginal infection				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Varicella				
subjects affected / exposed	1 / 906 (0.11%)			
occurrences (all)	1			
Viral infection				
subjects affected / exposed	5 / 906 (0.55%)			
occurrences (all)	6			
Viral pharyngitis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Viral upper respiratory tract infection				
subjects affected / exposed	4 / 906 (0.44%)			
occurrences (all)	4			
Vulvovaginal candidiasis				
subjects affected / exposed	2 / 906 (0.22%)			
occurrences (all)	2			
Vulvovaginal mycotic infection				
subjects affected / exposed	3 / 906 (0.33%)			
occurrences (all)	3			
Wound infection				

subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Laryngitis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Conjunctivitis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Conjunctivitis viral				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Ear lobe infection				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Fungal foot infection				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Fungal skin infection				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Gastrointestinal viral infection				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Hand-foot-and-mouth disease				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Helminthic infection				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Herpes simplex				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Pericoronitis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Parasitic gastroenteritis				

subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Post-acute COVID-19 syndrome				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Respiratory syncytial virus infection				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Skin bacterial infection				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Subcutaneous abscess				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Tinea pedis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Vaccination site cellulitis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Vaccination site pustule				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Vulvovaginitis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Laryngotracheitis obstructive				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Molluscum contagiosum				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Oral candidiasis				
subjects affected / exposed	0 / 906 (0.00%)			
occurrences (all)	0			
Pharyngotonsillitis				

subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Metabolism and nutrition disorders			
Insulin resistance			
subjects affected / exposed	3 / 906 (0.33%)		
occurrences (all)	3		
Iron deficiency			
subjects affected / exposed	3 / 906 (0.33%)		
occurrences (all)	3		
Lactose intolerance			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Obesity			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Type 2 diabetes mellitus			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Vitamin B complex deficiency			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Vitamin B12 deficiency			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Abnormal loss of weight			
subjects affected / exposed	1 / 906 (0.11%)		
occurrences (all)	1		
Folate deficiency			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Glucose tolerance impaired			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		
Gluten sensitivity			
subjects affected / exposed	0 / 906 (0.00%)		
occurrences (all)	0		

Hypercholesterolaemia subjects affected / exposed occurrences (all)	1 / 906 (0.11%) 1		
Hyperlipidaemia subjects affected / exposed occurrences (all)	1 / 906 (0.11%) 1		
Hyponatraemia subjects affected / exposed occurrences (all)	1 / 906 (0.11%) 1		
Zinc deficiency subjects affected / exposed occurrences (all)	1 / 906 (0.11%) 1		
Vitamin D deficiency subjects affected / exposed occurrences (all)	2 / 906 (0.22%) 2		
Decreased appetite subjects affected / exposed occurrences (all)	0 / 906 (0.00%) 0		
Haemochromatosis subjects affected / exposed occurrences (all)	0 / 906 (0.00%) 0		
Hypertriglyceridaemia subjects affected / exposed occurrences (all)	0 / 906 (0.00%) 0		
Hypoglycaemia subjects affected / exposed occurrences (all)	0 / 906 (0.00%) 0		
Hypovitaminosis subjects affected / exposed occurrences (all)	0 / 906 (0.00%) 0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
23 May 2019	As per the recommendation from CBER, the scope of the study has been extended to include the 3-dose (0,2,6-M) schedule and an additional 2-dose schedule (0,6-M) along with the 2-dose (0,2-M) schedule planned originally. The study will assess the immunogenicity of the 2-dose and 3-doses vaccination with rMenB+OMV NZ vaccine along with effectiveness and safety.
18 March 2020	The scope of this post-marketing commitment study has been extended to demonstrate the effectiveness, immunogenicity and safety of GSK's investigational combined meningococcal ABCWY vaccine (from a phase III MenABCWY study) along with the rMenB+OMV NZ vaccine.
23 September 2020	This protocol is amended primarily as a consequence of feedback from regulatory authorities of participating countries following their review of Protocol Amendment 2. Additional changes have been made to improve the clarity of the text.
09 May 2021	The protocol is being amended to document the increase in blood volumes drawn at certain visits (Visit 2 and Visit 6). The allowed windows for study visits during special circumstances have also been widened to maintain subject visit compliance during the COVID-19 pandemic. Additionally, considering that some of the study interventions are combination products constituted of a device and biologic product (pre-filled syringes), the amended protocol provides instructions for collection of safety information related to the use of medical devices. The reporting period for pregnancies has also been updated in line with the current guidelines

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported